US20200157165A1 - Peptides having osteoblast growth-promoting activity and use thereof - Google Patents
Peptides having osteoblast growth-promoting activity and use thereof Download PDFInfo
- Publication number
- US20200157165A1 US20200157165A1 US16/703,177 US201916703177A US2020157165A1 US 20200157165 A1 US20200157165 A1 US 20200157165A1 US 201916703177 A US201916703177 A US 201916703177A US 2020157165 A1 US2020157165 A1 US 2020157165A1
- Authority
- US
- United States
- Prior art keywords
- glu
- peptide
- ser
- pro
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 300
- 210000000963 osteoblast Anatomy 0.000 title claims abstract description 72
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 title abstract description 49
- 102000004196 processed proteins & peptides Human genes 0.000 title description 63
- 150000003839 salts Chemical class 0.000 claims abstract description 87
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 62
- 230000000694 effects Effects 0.000 claims abstract description 51
- 150000001413 amino acids Chemical class 0.000 claims abstract description 29
- 210000001612 chondrocyte Anatomy 0.000 claims abstract description 29
- 238000006467 substitution reaction Methods 0.000 claims abstract description 17
- 238000012217 deletion Methods 0.000 claims abstract description 8
- 230000037430 deletion Effects 0.000 claims abstract description 8
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 50
- 230000011164 ossification Effects 0.000 claims description 49
- 230000012010 growth Effects 0.000 claims description 47
- 108010015053 lipovitellin Proteins 0.000 claims description 43
- 230000001737 promoting effect Effects 0.000 claims description 32
- 208000015100 cartilage disease Diseases 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 28
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 27
- 239000000047 product Substances 0.000 claims description 27
- 206010061762 Chondropathy Diseases 0.000 claims description 26
- 208000012659 Joint disease Diseases 0.000 claims description 26
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 25
- 229920002674 hyaluronan Polymers 0.000 claims description 25
- 229960003160 hyaluronic acid Drugs 0.000 claims description 25
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 22
- 230000024245 cell differentiation Effects 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 241000124008 Mammalia Species 0.000 claims description 15
- 230000002648 chondrogenic effect Effects 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 15
- 239000002537 cosmetic Substances 0.000 claims description 14
- 230000010261 cell growth Effects 0.000 claims description 12
- 235000013373 food additive Nutrition 0.000 claims description 12
- 239000002778 food additive Substances 0.000 claims description 12
- 239000013589 supplement Substances 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 102000013275 Somatomedins Human genes 0.000 claims 10
- 230000006698 induction Effects 0.000 claims 10
- 230000030991 negative regulation of bone resorption Effects 0.000 claims 5
- 210000000988 bone and bone Anatomy 0.000 abstract description 85
- 210000004027 cell Anatomy 0.000 description 54
- 108010000912 Egg Proteins Proteins 0.000 description 40
- 102000002322 Egg Proteins Human genes 0.000 description 40
- 241000700159 Rattus Species 0.000 description 29
- 239000002609 medium Substances 0.000 description 28
- 235000001014 amino acid Nutrition 0.000 description 24
- 229940024606 amino acid Drugs 0.000 description 24
- 102000002265 Human Growth Hormone Human genes 0.000 description 22
- 108010000521 Human Growth Hormone Proteins 0.000 description 22
- 239000000854 Human Growth Hormone Substances 0.000 description 22
- 239000003531 protein hydrolysate Substances 0.000 description 22
- 238000005259 measurement Methods 0.000 description 20
- 108091033319 polynucleotide Proteins 0.000 description 19
- 102000040430 polynucleotide Human genes 0.000 description 19
- 239000002157 polynucleotide Substances 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 17
- -1 Aromatic amino acids Chemical class 0.000 description 14
- 210000002969 egg yolk Anatomy 0.000 description 14
- 239000013604 expression vector Substances 0.000 description 14
- 235000013345 egg yolk Nutrition 0.000 description 13
- 239000000411 inducer Substances 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 102000014429 Insulin-like growth factor Human genes 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 210000000845 cartilage Anatomy 0.000 description 12
- 239000013641 positive control Substances 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 11
- 229910052500 inorganic mineral Inorganic materials 0.000 description 11
- 235000010755 mineral Nutrition 0.000 description 11
- 239000011707 mineral Substances 0.000 description 11
- 210000002997 osteoclast Anatomy 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000002303 tibia Anatomy 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 239000007952 growth promoter Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 101710161186 Vitellogenin-2 Proteins 0.000 description 8
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 229960002378 oftasceine Drugs 0.000 description 8
- 238000003305 oral gavage Methods 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- 239000004098 Tetracycline Substances 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 230000037182 bone density Effects 0.000 description 7
- 210000004349 growth plate Anatomy 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229960002180 tetracycline Drugs 0.000 description 7
- 229930101283 tetracycline Natural products 0.000 description 7
- 235000019364 tetracycline Nutrition 0.000 description 7
- 150000003522 tetracyclines Chemical class 0.000 description 7
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000008468 bone growth Effects 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 238000005194 fractionation Methods 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000013425 morphometry Methods 0.000 description 6
- 201000008482 osteoarthritis Diseases 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 102000004067 Osteocalcin Human genes 0.000 description 5
- 108090000573 Osteocalcin Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000010392 Bone Fractures Diseases 0.000 description 4
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 4
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 4
- 208000020084 Bone disease Diseases 0.000 description 4
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 4
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 229940062527 alendronate Drugs 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 239000000413 hydrolysate Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 235000012149 noodles Nutrition 0.000 description 4
- 229940063137 norditropin Drugs 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 235000020937 fasting conditions Nutrition 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 206010007710 Cartilage injury Diseases 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 101800005135 Lipovitellin-2 Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 description 2
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037180 bone health Effects 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000991 chicken egg Anatomy 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 210000004268 dentin Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- YJLGBPOTRWZBFH-JTQLQIEISA-N (2s)-2-hydrazinyl-3-(1h-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(C[C@H](NN)C(O)=O)=CNC2=C1 YJLGBPOTRWZBFH-JTQLQIEISA-N 0.000 description 1
- SJTPYAOZAPSOLO-REOHCLBHSA-N (2s)-2-hydrazinyl-3-hydroxypropanoic acid Chemical compound NN[C@@H](CO)C(O)=O SJTPYAOZAPSOLO-REOHCLBHSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- PUBLUECXJRHTBK-ACZMJKKPSA-N Ala-Glu-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O PUBLUECXJRHTBK-ACZMJKKPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000002679 Alveolar Bone Loss Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 101710158100 Casein kinase II subunit beta Proteins 0.000 description 1
- 102100027992 Casein kinase II subunit beta Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010072132 Fracture pain Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010072970 Meniscus injury Diseases 0.000 description 1
- 208000037848 Metastatic bone disease Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 101000599952 Mus musculus Insulin-like growth factor I Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101100372804 Oryza sativa subsp. japonica VIT2 gene Proteins 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 101000599960 Rattus norvegicus Insulin-like growth factor I Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010049264 Teriparatide Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940118662 aluminum carbonate Drugs 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 150000003976 azacycloalkanes Chemical class 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002745 epiphysis Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000005009 osteogenic cell Anatomy 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 235000014594 pastries Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000007967 peppermint flavor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 229960002119 raloxifene hydrochloride Drugs 0.000 description 1
- BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 1
- 229960005460 teriparatide Drugs 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a peptide having osteoblast growth-promoting activity; a bone formation promoter, a bone resorption inhibitor, a chondrocyte growth promoter, a hyaluronic acid production promoter, a chondrogenic cell differentiation inducer, a mesenchymal stem cell growth promoter and a mesenchymal stem cell differentiation inducer, each comprising the peptide; and use thereof.
- Osteoporosis is a systemic disease that develops due to reduction of the bone volume or the bone mineral content and causes the breakage of the fine structure of bone, which reduces the bone strength and increases the risk of bone fracture.
- the number of patients with osteoporosis in Japan reaches about 11 million, and 80% of them are women. Osteoporosis mainly affects people in their middle or older age, and considering that the society is aging, the number of patients is expected to increase in the future. Another concern is that the incidence of bone fracture is increasing in elementary and junior high school students. In order to prevent osteoporosis, it is very important to substantially increase the bone mineral content during the young age, thus achieving a high peak bone mass. Thus the maintenance of bone health is now a social interest regardless of sex and age.
- Bone diseases are conventionally prevented or treated by dietary calcium supplementation, light exercise, sun bath, medication, etc.
- dietary calcium supplementation is done with calcium salts such as calcium carbonate and calcium phosphate, and natural calcium sources such as bovine bone powder, egg shells and fish bone powder.
- calcium salts such as calcium carbonate and calcium phosphate
- natural calcium sources such as bovine bone powder, egg shells and fish bone powder.
- Moderate exercise increases the bone volume and strengthens bone, and a stroll and a walk are good for bone health.
- Sun bath is considered to be good for supply of activated vitamin D 3 , but sun bath is insufficient for prevention or treatment of bone diseases.
- chondrocytes For the prevention or treatment of various chondropathies, the growth of chondrocytes and the expression of differentiation function are important. That is, the growth and maturation of chondrocytes are considered to promote normal growth of bone and repair bone fracture.
- TGF transforming growth factor
- IGF insulin-like growth factor
- bFGF basic fibroblast growth factor
- PTHrP PTH-related peptide
- HGF hepatocyte growth factor
- BMP bone morphogenetic protein
- osteoarthritis account for the largest proportion of chondropathy patients.
- One of the causes of osteoarthritis may be aging, and the incidence of the disease is expected to increase in this aging society.
- bone resorption inhibitors such as estrogen and calcitonin, aspirin, and nonsteroidal anti-inflammatory drugs (NSAIDs) have mostly been used for the prevention and treatment of cartilage disorders that manifest degeneration of cartilage as major symptoms, such as joint diseases.
- NSAIDs nonsteroidal anti-inflammatory drugs
- these drugs are not effective enough, and are well-known to cause adverse reactions such as digestive tract disorders. Under these circumstances, there has been a great demand for prophylactic or alleviating drugs that are safe for use in the treatment of cartilage injuries and cartilage disorders.
- an egg yolk-derived peptide comprising an amino acid sequence comprising at least Ala-Glu-Ser has osteoblast growth-promoting activity (see Patent Literature 1) and that an egg-yolk protein hydrolysate has chondrocyte growth-promoting activity (see Patent Literature 2).
- Patent Literature 1 an egg yolk-derived peptide comprising an amino acid sequence comprising at least Ala-Glu-Ser has osteoblast growth-promoting activity
- Patent Literature 2 an egg-yolk protein hydrolysate has chondrocyte growth-promoting activity
- Patent Literature 1 JP 2011-211979 A
- Patent Literature 2 WO 2014/007318
- An object of the present invention is to provide a novel peptide having bone formation-promoting effect and chondrocyte growth-promoting effect and to provide excellent applications of the peptide.
- the present invention has been made to solve the above problems and includes the following.
- a peptide having osteoblast growth-promoting activity having 100 amino acid residues or less comprising an amino acid sequence selected from
- a bone formation promoter comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- a bone resorption inhibitor comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- a chondrocyte growth promoter comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- a hyaluronic acid production promoter comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- a chondrogenic cell differentiation inducer comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- a mesenchymal stem cell growth promoter comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- a mesenchymal stem cell differentiation inducer comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- a medicament comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- a food or drink product comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- a supplement comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- a food additive comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- a cosmetic product comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- a method for promoting bone formation comprising administering, to a mammal, an effective amount of the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- a method for preventing or alleviating a cartilage disorder or a joint disease comprising administering, to a mammal, an effective amount of the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- the present invention provides a novel peptide having bone formation-promoting effect and chondrocyte growth-promoting effect.
- the peptide can promote bone formation via oral ingestion, and is thus useful as a medicament, a food or drink product, a supplement, a food additive, a cosmetic product, etc. that are for promoting bone formation or for preventing or alleviating a cartilage disorder or joint pain.
- FIG. 1 shows a chart showing the measurement results of the osteoblast growth-promoting activity of fractions resulting from fractionation of an egg-yolk protein hydrolysate with a UF membrane with a cut-off molecular weight of 1 kDa.
- FIG. 2 shows a chart showing the measurement results of the osteoblast growth-promoting activity of a non-adsorbed fraction (flow-through) and fractions eluted with sodium chloride solutions at concentrations of 750 mM and 1 M from an anion-exchange column loaded with a fraction with a molecular weight of 1 kDa or more obtained from the egg-yolk protein hydrolysate.
- FIG. 3 is a chart showing fractions resulting from reverse-phase HPLC fractionation of the 750 mM NaCl eluate fraction, which showed high osteoblast growth-promoting activity.
- FIG. 4 is a chart showing the measurement results of the osteoblast growth-promoting activity of G 1 to G 9 indicated in FIG. 3 .
- FIG. 5 is a chart showing the measurement results of the osteoblast growth-promoting activity of fractions 11 to 20 contained in G 3 and G 4 .
- FIG. 6 is a chart showing peaks detected in fraction 12 by HPLC under conditions different from those of the above HPLC.
- FIG. 7 is a chart showing the measurement results of the osteoblast growth-promoting activity of fractions with the two peaks indicated in FIG. 6 .
- FIG. 8 shows the analysis results of the structure of peptides.
- FIG. 9 is a chart showing the measurement results of the osteoblast growth-promoting activity of a synthetic peptide (No. 1 ).
- FIG. 10 is a chart showing the measurement results of the osteoblast growth-promoting activity of synthetic peptides (No. 2 and No. 3 ).
- FIG. 11 is a chart showing the measurement results of the osteoblast growth-promoting activity of synthetic peptides (No. 4 and No. 5 ).
- FIG. 12 is a chart showing the measurement results of the osteoblast growth-promoting activity of a synthetic peptide (No. 6 ).
- FIG. 13 is a chart showing the measurement results of the increased height of the tibial growth plates of rats after oral administration of a synthetic peptide (No. 1 ).
- FIG. 14 is a chart showing the measurement results of the chondrocyte growth-promoting activity of synthetic peptides (No. 1 and No. 6 ).
- FIG. 15 is a chart showing the measurement results of the hyaluronic acid production-promoting activity of synthetic peptides (No. 1 and No. 6 ).
- FIG. 16 shows the experimental protocol of Example 14.
- FIG. 17 is a chart showing the measurement results of the growth rate of the growth cartilage per day (in the longitudinal direction) in a synthetic peptide administration group.
- FIG. 18 shows fluorescent microscope images of the formation of primary cancellous bone in a synthetic peptide administration group.
- FIG. 19 is a chart showing an increase in the serum level of insulin-like growth factor (IGF-1) in a synthetic peptide administration group.
- IGF-1 insulin-like growth factor
- FIG. 20 shows the experimental protocol of Example 15.
- FIG. 21 is a chart showing the calculation results of the increased height of the rat tibiae per day in a synthetic peptide administration group.
- FIG. 22 is a chart showing the measurement results of the secondary cancellous bone volume relative to the bone tissue volume in rats in a synthetic peptide administration group.
- FIG. 23 is a chart showing the measurement results of the percentage of the bone surface occupied by osteoblasts relative to the total bone surface in a synthetic peptide administration group.
- FIG. 24 is a chart showing the measurement results of the percentage of the bone surface occupied by osteoclasts relative to the total bone surface in a synthetic peptide administration group.
- FIG. 25 shows the experimental protocol of Example 16.
- FIG. 26 is a chart showing the calculation results of the mineral apposition rate, per day, in the secondary cancellous bone of rats in a synthetic peptide administration group.
- FIG. 27 is a chart showing the measurement results of the percentage of the bone surface occupied by osteoblasts relative to the total bone surface in a synthetic peptide administration group.
- FIG. 28 is a chart showing the measurement results of the number of osteoblasts relative to the bone tissue volume in rats in a synthetic peptide administration group.
- FIG. 29 is a chart showing the calculation results of the bone formation rate in a synthetic peptide administration group.
- the present invention provides a peptide having osteoblast growth-promoting activity.
- the inventors investigated the identification of peptides with strong activity for promoting the growth of osteoblasts from a peptide mixture obtained by hydrolysis of egg yolk proteins, and isolated the peptides consisting of the amino acid sequences (i) to (vi) shown below.
- the amino acid sequences (ii) to (vi) are partial sequences of the amino acid sequence (i).
- the peptide provided by the present invention is a peptide having osteoblast growth-promoting activity, comprising an amino acid sequence selected from
- the peptide of the present invention may be a peptide consisting of the amino acid sequence (a), (b) or (c), or a peptide comprising the amino acid sequence (a), (b) or (c) and an amino acid sequence other than (a), (b) or (c).
- the amino acid sequence other than (a), (b) or (c) is not particularly limited as long as the peptide retains osteoblast growth-promoting activity.
- the amino acid sequence other than (a), (b) or (c) may be, for example, a tag sequence (e.g., a polyhistidine tag, a Myc tag, a FLAG tag, etc.).
- the number of the amino acid residues contained in the peptide of the present invention is not particularly limited, but is preferably 1000 or less, more preferably 500 or less, further more preferably 200 or less, further more preferably 100 or less, further more preferably 80 or less, further more preferably 70 or less, further more preferably 60 or less, further more preferably 50 or less, further more preferably 40 or less, further more preferably or less, further more preferably 20 or less, particularly preferably 15 or less.
- the minimum number of the amino acid residues is not particularly limited as long as the peptide retains osteoblast growth-promoting activity, but the minimum number of the amino acid residues is preferably 3 or more, more preferably 4 or more, further more preferably 5 or more.
- the peptide of the present invention is, hence, preferably a fragment of vitellogenin-2 that contains at least four contiguous amino acids at positions 1060 to 1074 of vitellogenin-2 and has osteoblast growth-promoting activity.
- Vitellogenin-2 is a precursor protein contained in an egg yolk, and is known to be cleaved into four yolk proteins: lipovitellin-1, phosvitin, lipovitellin-2 and YGP40 (yolk glycoprotein of 40 kDa) (see the database UniProt: P02845 (VIT2 CHICK)). Positions 1060 to 1074 of vitellogenin-2 corresponds to positions 1045 to 1059 of the amino acid sequence of lipovitellin-1 (SEQ ID NO: 8).
- the peptide of the present invention is, hence, preferably a fragment of lipovitellin-2 that contains at least four contiguous amino acids at positions 1045 to 1059 of lipovitellin-1 and has osteoblast growth-promoting activity.
- the peptide of the present invention is a peptide consisting of any of the amino acid sequences (i) to (vi).
- conservative substitutions of amino acids means substitution of an amino acid for another one within the same group shown in Table 1 below.
- preferred conservative substitutions of amino acids include a substitution between aspartic acid and glutamic acid, a substitution among arginine, lysine, and histidine, a substitution between tryptophan and phenylalanine, a substitution between phenylalanine and valine, a substitution among leucine, isoleucine and alanine, and a substitution between glycine and alanine.
- the peptide derivative of the present invention is derived from a peptide with a particular amino acid sequence and the C-terminus of the peptide derivative may be a carboxyl group (—COOH), a carboxylate (—COO ⁇ ), an amide (—CONH 2 ) or an ester (—COOR).
- R of the ester examples include C 1-6 alkyl groups such as methyl, ethyl, n-propyl, isopropyl and n-butyl; C 3-8 cycloalkyl groups such as cyclopentyl and cyclohexyl; C 6-12 aryl groups such as phenyl and ⁇ -naphthyl; C 7-14 aralkyl groups including phenyl-C 1-2 alkyl groups, such as benzyl and phenethyl, and ⁇ -naphthyl-C 1-2 alkyl groups, such as ⁇ -naphthylmethyl; and a pivaloyloxymethyl group, which is commonly used as an ester for oral administration.
- C 1-6 alkyl groups such as methyl, ethyl, n-propyl, isopropyl and n-butyl
- C 3-8 cycloalkyl groups such as cyclopentyl and cycl
- the amide examples include an amide; an amide substituted with one or two C 1-6 alkyl groups; an amide substituted with one or two C 1-6 alkyl groups substituted with a phenyl group; and an amide that forms a 5- to 7-membered azacycloalkane containing the nitrogen atom of the amide group.
- the peptide of the present invention has a carboxyl group or a carboxylate at a position other than the C-terminus, those with amidated or esterified carboxyl or carboxylate are also included in the peptide derivative of the present invention.
- the peptide derivative of the present invention also includes the peptides of the present invention in which the N-terminal amino group is protected with a protecting group (e.g., a C 1-6 acyl group including a formyl group and C 2-6 alkanoyl groups such as acetyl), the peptides of the present invention in which a N-terminal glutamyl group generated by in vivo cleavage of the N-terminus is converted to a pyroglutamate, and the peptides of the present invention in which a substituent (e.g., —OH, —SH, an amino group, an imidazole group, an indole group, or a guanidino group) on an amino acid side chain in the molecule is protected with a suitable protecting group (e.g., a C 1-6 acyl group including a formyl group and C 2-6 alkanoyl groups such as acetyl).
- a protecting group e.g.,
- the side chains of the amino acids constituting the peptide derivative of the present invention may be modified with a substituent.
- substituents include, but are not limited to, a fluorine atom, a chlorine atom, a cyano group, a hydroxy group, a nitro group, an alkyl group, a cycloalkyl group, an alkoxy group, an amino group, and a phosphate group.
- the side-chain substituent may be protected with a protecting group.
- the derivative of the peptide of the present invention also includes glycopeptides, which are peptides having sugar chains.
- the peptide of the present invention or a derivative thereof may form a salt.
- the salt is preferably physiologically acceptable.
- the physiologically acceptable salt include salts with acids such as hydrochloric acid, sulfuric acid, phosphoric acid, lactic acid, tartaric acid, maleic acid, fumaric acid, oxalic acid, malic acid, citric acid, oleic acid, and palmitic acid; salts with hydroxides or carbonates of an alkali metal, such as sodium, potassium and calcium, salts with hydroxides or carbonates of an alkaline earth metal, and salts with aluminum hydroxide or carbonate; and salts with triethylamine, benzylamine, diethanolamine, t-butylamine, dicyclohexylamine, arginine, etc.
- the peptide of the present invention or a derivative thereof may comprise a D-amino acid or a non-naturally occurring amino acid to the extent that the peptide or derivative retains its characteristics.
- the peptide of the present invention or a derivative thereof may comprise another substance linked thereto to the extent that the peptide or derivative retains its characteristics. Examples of the substance linkable to the peptide include other peptides, lipids, sugars, sugar chains, an acetyl group, and naturally occurring or synthetic polymers.
- the peptide of the present invention may be subjected to modification such as glycosylation, side-chain oxidation, and phosphorylation to the extent that the resulting modified peptide retains the characteristics of the original peptide.
- the peptide of the present invention or a derivative thereof or a salt thereof preferably has at least one phosphorylated serine.
- the position of the phosphorylated serine is not particularly limited, but preferably at least one of the serine residues at positions 5, 11 and 12 of the amino acid sequence of SEQ ID NO: 1 is phosphorylated, more preferably at least one of the serine residues at positions 5 and 11 is phosphorylated, and further more preferably the serine residues at positions 5 and 11 are phosphorylated. Phosphorylation of the serine residue(s) has been shown to result in an increase in the effect of promoting the growth of bone-forming cells.
- Preferred peptide derivatives of the present invention are peptides with a phosphorylated serine residue represented by the amino acid sequences of SEQ ID NOs: 9 to 14 (see FIG. 10 ).
- the peptide of the present invention or a derivative thereof or a salt thereof can be produced by solid-phase synthesis (the Fmoc or Boc method) or liquid-phase synthesis in accordance with a known standard peptide synthesis protocol.
- the peptide of the present invention can be produced by using a transformant carrying an expression vector containing a DNA encoding the peptide of the present invention.
- the peptide of the present invention can be produced by preparing a peptide using a transformant carrying an expression vector containing a DNA encoding a peptide comprising the peptide of the present invention, and cleaving the resulting peptide with a suitable protease or peptidase.
- the peptide of the present invention can be produced by a method using an in vitro transcription-translation system.
- the peptide of the present invention can be obtained by purifying a hydrolysate of chicken egg yolk proteins.
- the preparation method of a hydrolysate of egg yolk proteins and the purification method of the peptide are not particularly limited, and the preparation and purification may be done by a known method selected as appropriate.
- the peptide can be obtained by, for example, preparing a defatted egg yolk powder, then preparing a hydrolysate from the powder using an enzyme such as a protease, and purifying a peptide of interest from the hydrolysate by ultrafiltration or chromatography such as HPLC.
- Whether the peptide of interest has osteoblast growth-promoting activity can be determined by comparing the growth of osteoblasts between the culture in the presence of the peptide and the culture in the absence of the peptide in a test system selected as appropriate from known methods for measuring the cell growth. A higher growth level of osteoblasts in the culture in the presence of the peptide indicates that the peptide has the promoting activity.
- MTT assay or cell counting method may be performed in a cell culture system
- Whether the peptide of interest has chondrocyte growth-promoting activity can be determined by comparing the growth of chondrocytes or chondrogenic cells between the culture in the presence of the peptide and the culture in the absence of the peptide in a test system selected as appropriate from known methods for measuring the cell growth. A higher growth level of osteoblasts in the culture in the presence of the peptide indicates that the peptide has the promoting activity.
- MTT assay or cell counting method may be performed in a cell culture system using an osteoblast-derived cell line.
- Whether the peptide of interest has hyaluronic acid production-promoting activity can be determined by measuring, by a known method, the amounts of hyaluronic acid production in the culture supernatant in culture using cultured cells with an ability to produce hyaluronic acid, and then comparing the amounts of hyaluronic acid between the culture in the presence of the peptide and the culture in the absence of the peptide. A higher amount of hyaluronic acid in the supernatant of the culture in the presence of the peptide indicates that the peptide has the promoting activity. Examples of the measurement method of the amount of hyaluronic acid include ELISA.
- the polynucleotide provided by the present invention is a polynucleotide encoding the above peptide of the present invention.
- the polynucleotide can be present in the form of RNA (e.g., mRNA) or DNA (e.g., cDNA or genomic DNA).
- the polynucleotide may be a double or single strand.
- the double strand may be a double-stranded DNA, a double-stranded RNA or a DNA-RNA hybrid.
- the single strand may be a coding strand (sense strand) or a non-coding strand (antisense strand).
- the polynucleotide of the present invention may be fused with a polynucleotide encoding a tag label (a tag sequence or a marker sequence) at the 5′- or 3′-terminus.
- the polynucleotide of the present invention may contain an untranslated region (UTR) sequence, a vector sequence (including an expression vector sequence), etc.
- the nucleotide sequence of the polynucleotide encoding the peptide of the present invention can be custom designed by appropriately selecting codons for amino acids based on the amino acid sequence of the peptide of the present invention and combining the selected codons.
- the amino acid sequence of SEQ ID NO: 1 is part of the amino acid sequence of vitellogenin-2 (SEQ ID NO: 7), which is a precursor protein contained in an egg yolk, and therefore the nucleotide sequence of the polynucleotide can be designed based on the nucleotide sequence of the gene encoding vitellogenin-2.
- the polynucleotide of the present invention can be produced by a known DNA synthesis method, PCR, etc.
- the nucleotide sequence is designed by appropriately selecting codons for amino acids based on the amino acid sequence of the peptide of the present invention, and the designed sequence is chemically synthesized using a commercially available DNA synthesizer.
- primers are designed for amplification of the coding region of the peptide of the present invention in the nucleotide sequence of the gene encoding vitellogenin-2 (accession No.: X13607), and then PCR etc. are performed with chicken genomic DNA or cDNA as a template using the designed primers to produce a DNA fragment containing the polynucleotide of the present invention in large quantities.
- the present invention provides an expression vector used for the production of the peptide of the present invention.
- the expression vector of the present invention is not particularly limited as long as it contains a polynucleotide encoding the peptide of the present invention, but preferred are plasmid vectors carrying a RNA polymerase recognition sequence (pSP64, pBluescript, etc.).
- the method for preparing the expression vector is not particularly limited, and the expression vector may be prepared with the use of a plasmid, a phage, a cosmid or the like.
- the type of the vector is not particularly limited and any appropriate vector that can be expressed in host cells can be selected.
- a promoter sequence is selected as appropriate for the type of host cells to ensure the expression of the polynucleotide of the present invention, and this promoter sequence and the polynucleotide of the present invention are inserted into a plasmid etc. to give a desired expression vector.
- the peptide of the present invention can be collected and purified from the culture products etc. by conventional methods (e.g., filtration, centrifugation, cell disruption, gel filtration chromatography, ion exchange chromatography, etc.).
- the expression vector preferably contains at least one selection marker.
- the marker include a dihydrofolate reductase gene and a neomycin resistance gene for eukaryote cell culture; and a tetracycline resistance gene and an ampicillin resistance gene for culture of Escherichia coli and other bacteria.
- a selection marker is useful for checking whether the polynucleotide of the present invention has been successfully transfected into host cells and whether the polynucleotide is reliably expressed therein.
- the peptide of the present invention may be expressed as a fusion protein.
- the peptide of the present invention may be expressed as, for example, a GFP fusion protein using green fluorescent protein (GFP) of Aequorea victoria as a marker.
- GFP green fluorescent protein
- the host is not particularly limited and various known cells can suitably be used.
- the cells include bacteria such as Escherichia coli , yeasts (budding yeast Saccharomyces cerevisiae and fission yeast Schizosaccharomyces pombe ), nematodes ( Caenorhabditis elegans ), Xenopus laevis oocytes and animal cells (e.g., CHO cells, COS cells and Bowes melanoma cells).
- the method for transfecting host cells with the expression vector i.e. the transformation method, is also not particularly limited and known methods can suitably be used, including electroporation, the calcium phosphate method, the liposome method and the DEAE dextran method.
- the present invention provides a transformant carrying the expression vector of the present invention.
- the transformant encompasses a cell, a tissue and an organ as well as an individual organism.
- the type of the organism to be transformed is not particularly limited, and examples thereof include various microorganisms, plants and animals listed above as examples of the host cells.
- the transformant of the present invention expresses the peptide of the present invention. It is preferred that the transformant of the present invention stably expresses the peptide of the present invention, but the transformant may transiently express the peptide.
- Bone Formation Promoter Bone Resorption Inhibitor, Chondrocyte Growth Promoter, Hyaluronic Acid Production Promoter, Chondrogenic Cell Differentiation Inducer, Mesenchymal Stem Cell Growth Promoter, and Mesenchymal Stem Cell Differentiation Inducer
- the present invention provides a bone formation promoter comprising the peptide of the present invention. Since the peptide of the present invention has bone formation-promoting activity, the peptide is suitable as an active ingredient for a bone formation promoter.
- the bone formation-promoting activity of the peptide of the present invention can be confirmed by, for example, administering (e.g., oral administering) the peptide of the present invention to an animal subject for a certain period of time (e.g., for 7, 14 or 21 days), and measuring an indicator for the activity, including an enhanced increase in the height of the tibial growth plate, an increase in the growth rate of the growth cartilage, promotion of the formation of the primary cancellous bone, an increase in the serum level of insulin-like growth factor (IGF-1), an increase in the secondary cancellous bone volume relative to the bone tissue volume, an increase of osteoblasts, a reduction of osteoclasts, an increase in the mineral apposition rate in the secondary cancellous bone, etc.
- administering e.g., oral administer
- growth cartilage herein refers to, for example, the growing area of the bone at the epiphysis.
- primary cancellous bone refers to, for example, immature cancellous bone immediately below the growth cartilage.
- secondary cancellous bone refers to, for example, mature cancellous bone.
- the term “promotion of bone formation” herein can be understood as “an enhanced increase in the height of the tibial growth plate”, “an increase in the growth rate of the growth cartilage”, “promotion of the formation of the primary cancellous bone”, “an increase in the serum level of insulin-like growth factor (IGF-1)”, “an increase in the secondary cancellous bone volume relative to the bone tissue volume”, “an increase of osteoblasts”, “a reduction of osteoclasts”, “an increase in the mineral apposition rate in the secondary cancellous bone”, etc.
- the present invention also provides an osteoblast growth promotor comprising the peptide of the present invention. Since the peptide of the present invention has osteoblast growth-promoting activity, the peptide is suitable as an active ingredient for an osteoblast growth promotor.
- the present invention also provides a bone resorption inhibitor comprising the peptide of the present invention.
- the peptide of the present invention has bone resorption-inhibiting activity, and is thus suitable as an active ingredient for a bone resorption inhibitor.
- the present invention also provides a chondrocyte growth promotor comprising the peptide of the present invention. Since the peptide of the present invention has chondrocyte growth-promoting activity, the peptide is suitable as an active ingredient for a chondrocyte growth promoter.
- the present invention also provides a hyaluronic acid production promoter comprising the peptide of the present invention.
- the peptide of the present invention Since the peptide of the present invention has hyaluronic acid production-promoting activity, the peptide is suitable as an active ingredient for a hyaluronic acid production promoter.
- the present invention also provides a chondrogenic cell differentiation inducer comprising the peptide of the present invention. Since the peptide of the present invention has differentiation inducing activity on chondrogenic cells, the peptide is suitable as an active ingredient for a chondrogenic cell differentiation inducer.
- the present invention also provides a mesenchymal stem cell growth promoter comprising the peptide of the present invention.
- the peptide of the present invention has growth-promoting activity on mesenchymal stem cells, and is thus suitable as an active ingredient for a mesenchymal stem cell growth promoter.
- the present invention also provides a mesenchymal stem cell differentiation inducer comprising the peptide of the present invention.
- the peptide of the present invention has differentiation inducing activity on mesenchymal stem cells, and is thus suitable as an active ingredient for a mesenchymal stem cell differentiation inducer.
- lipovitellin-1 or a derivative thereof or a salt thereof is also suitable as an active ingredient for the above promoter, inhibitor or inducer.
- the lipovitellin-1 herein refers to a protein that consists of an amino acid sequence identical or substantially identical to the amino acid sequence of SEQ ID NO: 8 and has substantially the same activity as that of lipovitellin-1.
- the amino acid sequence substantially identical to the amino acid sequence of SEQ ID NO: 8 is, for example, an amino acid sequence derived from SEQ ID NO: 8 by deletion, substitution or addition of one to several amino acids.
- deletion, substitution or addition of one to several amino acids means deletion, substitution or addition of amino acids whose number is substantially equal to the number of the residues that can be deleted, substituted or added by a known method for mutagenesis of peptides, such as site-directed mutagenesis (preferably 10 amino acids or less, more preferably 7 amino acids or less, and even more preferably 5 amino acids or less).
- site-directed mutagenesis preferably 10 amino acids or less, more preferably 7 amino acids or less, and even more preferably 5 amino acids or less.
- Such a mutant protein is not limited to a protein artificially mutated by a known method for mutagenesis of polypeptides, and may be a protein isolated and purified from nature.
- amino acid sequence substantially identical to the amino acid sequence of SEQ ID NO: 1 is, for example, an amino acid sequence that is at least 80% identical, more preferably at least 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 1.
- a derivative of lipovitellin-1 is preferably those listed above as the examples of the derivative of the peptide of the present invention.
- a salt of lipovitellin-1 or of a derivative of lipovitellin-1 is preferably those listed above as the examples of the salt of the peptide of the present invention or of the derivative of the peptide of the present invention.
- Lipovitellin-1, a derivative thereof and a salt thereof can be produced as a recombinant protein by known genetic modification techniques or by methods using in vitro transcription-translation system.
- lipovitellin-1, a derivative thereof and a salt thereof can be purified from chicken egg yolk proteins.
- peptide etc. of the present invention encompasses lipovitellin-1, a derivative thereof and a salt thereof in addition to “the peptide of the present invention”.
- the peptide etc. of the present invention have been shown to exhibit the desired effects through oral administration to a mammal, and thus the above promoters, inhibitors and inducers are suitable for oral administration.
- the peptide etc. of the present invention which are the egg yolk protein lipovitellin-1 or a fragment thereof, are highly safe and have mild effects, and thus can be administered or used for a long period of time.
- the present invention provides a medicament comprising the peptide etc. of the present invention. Since the peptide etc. of the present invention have osteoblast growth-promoting activity, the peptide etc. can be used as a medicament for promoting bone formation.
- the medicament for promoting bone formation of the present invention can be suitable as a medicament for preventing or treating, for example, osteoporosis, osteogenesis imperfecta, hypercalcemia, hyperparathyroidism, osteomalacia, osteohalisteresis, osteolytic bone disease, osteonecrosis, Paget's disease, rheumatoid arthritis, bone loss due to osteoarthritis, inflammatory arthritis, osteomyelitis, glucocorticoid treatment, metastatic bone disease, periodontal bone loss, cancerous bone loss, age-related bone loss, fracture, and low back pain.
- the peptide etc. of the present invention have chondrocyte growth-promoting activity and/or hyaluronic acid production-promoting activity
- the peptide etc. can be used as a medicament for preventing or alleviating a cartilage disorder or a joint disease.
- cartilage disorder include osteoarthritis, cartilage defects, cartilage injury, and meniscus injury.
- joint disease include joint pain, rheumatoid arthritis, osteoarthritis, suppurative arthritis, gouty arthritis, traumatic arthritis, and degenerative joint disease.
- the medicament of the present invention can be produced by appropriately blending the peptide etc. of the present invention as an active ingredient with a pharmaceutically acceptable carrier or additive in accordance with a known production method for pharmaceutical preparations (e.g., the methods described in the Japanese pharmacopoeia, etc.).
- the medicament may be, for example, an oral preparation or a parenteral preparation, including tablets (including sugar-coated tablets, film-coated tablets, sublingual tablets, orally disintegrating tablets, and buccal tablets), pills, powders, granules, capsules (including soft capsules and microcapsules), troches, syrups, liquids, emulsions, suspensions, controlled-release preparations (e.g., fast-release preparations, sustained release preparations, and sustained release microcapsules), aerosols, films (e.g., orally disintegrating films, and oral mucosal adhesive films), injections (e.g., subcutaneous injections, intravenous injections, intramuscular injections, and intraperitoneal injections), intravenous infusions, transdermal preparations, ointments, lotions, patches, suppositories (e.g., rectal suppositories and vaginal suppositories), pellets, transnasal preparations, transpulmonary preparations (
- the amount of the carrier or additive to be added can be determined as appropriate based on the range typically used in the pharmaceutical field.
- the carrier or additive that may be added is not particularly limited and examples thereof include various types of carriers such as water, physiological saline, other aqueous solvents, and aqueous or oily vehicles; and various types of additives such as excipients, binders, pH adjusters, disintegrants, absorption promoters, lubricants, colorants, flavors and fragrances.
- additives examples include binders such as gelatin, corn starch, tragacanth, and gum arabic; excipients such as crystalline cellulose; swelling agents such as corn starch, gelatin, and alginic acid; lubricants such as magnesium stearate; sweeteners such as sucrose, lactose, and saccharin; and flavors such as peppermint flavor, wintergreen oil, and cherry flavor.
- a liquid carrier such as oils and fats can be further added in addition to the above types of materials.
- a sterile composition for injection can be prepared in accordance with a usual pharmaceutical practice (for example, by dissolving or suspending the active ingredient in a solvent such as water for injection or a natural vegetable oil).
- Aqueous liquids for injection that may be used are, for example, physiological saline and an isotonic solution containing glucose and/or other auxiliary substances (for example, D-sorbitol, D-mannitol, sodium chloride, etc.).
- the aqueous liquids for injection may be used in combination with an appropriate solubilizer, such as alcohols (e.g., ethanol), polyalcohols (e.g., propylene glycol, polyethylene glycol, etc.), and nonionic surfactants (e.g., polysorbate 80TM, HCO-50, etc.).
- solubilizer such as alcohols (e.g., ethanol), polyalcohols (e.g., propylene glycol, polyethylene glycol, etc.), and nonionic surfactants (e.g., polysorbate 80TM, HCO-50, etc.).
- Oily liquids that may be used are, for example, sesame oil and soybean oil.
- the oily liquids may be used in combination with a solubilizer such as benzyl benzoate and benzyl alcohol.
- buffering agents e.g., a phosphate buffer, a sodium acetate buffer, etc.
- soothing agents e.g., benzalkonium chloride, procaine hydrochloride, etc.
- stabilizers e.g., human serum albumin, polyethylene glycol, etc.
- preservatives e.g., benzyl alcohol, phenol, etc.
- the preparations produced in the above manner are safe and have low toxicity, and thus can be administered to, for example, humans and other mammals (e.g., rats, mice, rabbits, sheep, pigs, cows, cats, dogs, monkeys, etc.).
- mammals e.g., rats, mice, rabbits, sheep, pigs, cows, cats, dogs, monkeys, etc.
- the amount of the peptide etc. of the present invention in the medicament of the present invention may vary with the dosage form, the administration method, the carrier to be used, etc., but is usually 0.01 to 100% (w/w), preferably 0.1 to 95% (w/w), relative to the total amount of the preparation.
- the medicament of the present invention containing the peptide etc. of the present invention in such an amount can be produced in accordance with a conventional method.
- the dosage varies with the subject to which the medicament is to be administered, the symptom, the route of administration, etc., but in general, the dosage for oral administration to a human with a body weight of about 60 kg is about 0.01 to 1000 mg per day, preferably about 0.1 to 100 mg per day, and more preferably about 0.5 to 500 mg per day.
- the total daily dosage may be administered in a single dose or in divided doses.
- the medicament of the present invention is expected to exhibit a high additive or synergistic effect in combination with another medicament for treating a bone disease or for treating a cartilage or joint disease.
- Said another medicament for promoting bone formation may be, for example, an active vitamin D 3 preparation, a vitamin K 2 preparation, a parathyroid hormone preparation (teriparatide), a female hormone preparation (estrogen), a bisphosphonate preparation, a SERM (raloxifene hydrochloride), a calcitonin preparation, etc.
- Said another medicament for treating a cartilage or joint disease may be, for example, glucosamine, chondroitin, type I collagen, type II collagen, N-acetylglucosamine, etc.
- the present invention provides a food or drink product comprising the peptide etc. of the present invention.
- the food or drink product of the present invention is suitable as a food or drink product for promoting bone formation and as a food or drink product for preventing and/or alleviating a cartilage disorder or a joint disease.
- the food or drink product includes health foods, functional foods, foods for specified health use, and foods for sick people.
- the form of the food or drink product is not particularly limited and examples thereof include drinks such as tea drink, refreshing drink, carbonated drink, nutritional drink, fruit juice, and lactic drink; noodles such as buckwheat noodle, wheat noodle, Chinese noodle, and instant noodle; sweets and bakery products such as drop, candy, gum, chocolate, snack, biscuit, jelly, jam, cream, pastry, and bread; fishery and livestock products such as fish sausage, ham, and sausage; dairy products such as processed milk and fermented milk; fats, oils, and processed foods thereof, such as vegetable oil, oil for deep frying, margarine, mayonnaise, shortening, whipped cream, and dressing; seasonings such as sauce and dipping sauce; retort pouch foods such as curry, stew, rice-bowl cuisine, porridge, and rice soup; and frozen desserts such as ice cream, sherbet, and shaved ice.
- the present invention also provides a supplement comprising the peptide etc. of the present invention.
- the supplement of the present invention is suitable as a supplement for promoting bone formation and as a supplement for preventing and/or alleviating a cartilage disorder or a joint disease.
- the supplement can be provided in the form of, for example, tablets, granules, powders or drinks.
- the present invention provides a food additive comprising the peptide etc. of the present invention.
- the food additive of the present invention is suitable as a food additive for promoting bone formation and as a food additive for preventing and/or alleviating a cartilage disorder or a joint disease.
- the form of the food additive of the present invention is not particularly limited, and may be, for example, a liquid, a paste, a powder, flakes, granules, etc.
- the food additive of the present invention can be produced in accordance with a conventional production method for food additives.
- the present invention provides a cosmetic product comprising the peptide etc. of the present invention.
- the cosmetic product of the present invention is suitable as a cosmetic product for promoting bone formation and as a cosmetic product for preventing and/or alleviating a cartilage disorder or a joint disease.
- the cosmetic product includes the so-called medicated cosmetics (quasi drugs).
- examples of the cosmetic product include washing lotions, shampoos, rinses, hair tonics, hair lotions, aftershave lotions, body lotions, makeup lotions, cleansing creams, massage creams, emollient creams, aerosol products, deodorizers, fragrances, deodorants, and bath fragrances.
- the cosmetic product of the present invention may contain a component generally used in cosmetic products in addition to the peptide of the present invention, and such a component includes, for example, surfactants, moisturizers, animal- and plant-derived fats and oils, silicones, higher alcohols, lower alcohols, animal- and plant-derived extracts, ultraviolet absorbers, anti-inflammatories, sequestering agents, vitamins, antioxidants, thickeners, preservatives, bactericides, pH adjusters, colorants, and various fragrances.
- a component includes, for example, surfactants, moisturizers, animal- and plant-derived fats and oils, silicones, higher alcohols, lower alcohols, animal- and plant-derived extracts, ultraviolet absorbers, anti-inflammatories, sequestering agents, vitamins, antioxidants, thickeners, preservatives, bactericides, pH adjusters, colorants, and various fragrances.
- the present invention further includes the following.
- a method for promoting bone formation comprising administering, to a mammal, an effective amount of the peptide of the present invention or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- a method for preventing or alleviating a cartilage disorder or a joint disease comprising administering, to a mammal, an effective amount of the peptide of the present invention or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- a non-therapeutic method for promoting bone formation comprising orally administering, to a mammal, the peptide of the present invention or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- a non-therapeutic method for preventing or alleviating a cartilage disorder or a joint disease comprising orally administering, to a mammal, the peptide of the present invention or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- a defatted egg yolk powder prepared from a commercially available egg yolk powder may be used. Specifically, 5 to 10 parts by mass of ethanol (or n-hexane) is added to 1 part by mass of a commercially available egg yolk powder, then the mixture is stirred with a blender for about 30 minutes and filtered, and the solid is collected. This procedure is repeated about 3 times for removal of the fat from the egg yolk. The defatted egg yolk is then air-dried to give a defatted dry powder.
- a mouse osteoblast-like cell line MC3T3-E1 Subclone-4 (ATCC No. CRL-2593) was cultured in ⁇ -MEM medium supplemented with 10% FBS at 5% CO 2 and 95% air at 37° C. until confluent. The cells were collected by trypsinization. The collected cells were suspended at 1 ⁇ 10 4 cells/mL in fresh ⁇ -MEM medium. One mL of the cell suspension was seeded in each well of a 24-well plate, and precultured at 5% CO 2 and 95% air at 37° C.
- the medium was replaced with medium prepared by well mixing 50 ⁇ L of a sample or PBS ( ⁇ ) with 950 ⁇ L of fresh ⁇ -MEM medium supplemented with CaCl 2 to a Ca concentration of 500 ⁇ g/mL.
- the cells were further cultured for 72 hours.
- the growth activity of osteoblasts was measured by the cell counting method.
- the activity of the sample for promoting the growth of osteoblasts was expressed in terms of the relative value, with the growth rate in the PBS ( ⁇ ) group taken as 100.
- the egg-yolk protein hydrolysate was dissolved in 600 mL of water.
- the solution was fractionated with a UF membrane (cut off molecular weight: 1 kDa, Nihon Millipore, Ltd.). Osteoblast growth-promoting activity was determined for a fraction with a molecular weight of 1 kDa or less and a fraction with a molecular weight of 1 kDa or more.
- the unfractionated egg-yolk protein hydrolysate (1 mg/mL) was used.
- the fraction with a molecular weight of 1 kDa or less and the fraction with a molecular weight of 1 kDa or more were used in amounts equal to the corresponding amounts in the unfractionated egg-yolk protein hydrolysate (i.e., the corresponding amounts in 0.2 mg of the egg-yolk protein hydrolysate).
- the unfractionated egg-yolk protein hydrolysate (1 mg/mL) was used.
- the fractions were used in amounts equal to the corresponding amounts in the unfractionated egg-yolk protein hydrolysate (i.e., the corresponding amounts in 10 mg of the egg-yolk protein hydrolysate).
- the 750 mM NaCl eluate fraction which showed the highest osteoblast growth-promoting activity in the above (4), was further fractionated on a C18 reverse-phase column (column size: 50 mm in diameter ⁇ 250 mm). The fractions were collected at 1 minute intervals from elution time zero to 45 minute.
- the HPLC conditions were as follows.
- G 1 to G 9 fractions were collected, and every five fractions were combined to give G 1 to G 9 fractions (see FIG. 3 ). Osteoblast growth-promoting activity was determined for G 1 to G 9 fractions.
- the fractions were used in amounts equal to the corresponding amounts in the unfractionated egg-yolk protein hydrolysate (i.e., the corresponding amounts in 66 mg of the egg-yolk protein hydrolysate).
- the unfractionated egg-yolk protein hydrolysate (1 mg/mL) was used.
- Osteoblast growth-promoting activity was further determined for the five fractions (fractions 11 to 15 ) of G 3 and the five fractions (fractions 16 to 20 ) of G 4 .
- the fractions were used in amounts equal to the corresponding amounts in the unfractionated egg-yolk protein hydrolysate (i.e., the corresponding amounts in 66 mg of the egg-yolk protein hydrolysate).
- the unfractionated egg-yolk protein hydrolysate (1 mg/mL) was used.
- HPLC was performed on fractions 11 to 20 under the following conditions.
- fraction 12 was subjected to HPLC under the above conditions, and fractions with peak 1 and peak 2 were separated (see FIG. 6 ). Osteoblast growth-promoting activity was determined for the fraction with peak 1 (peak 1 ), the fraction with peak 2 (peak 2 ), and a fraction other than peak 1 and peak 2 fractions (Others).
- the fractions were used in amounts equal to the corresponding amounts in the unfractionated egg-yolk protein hydrolysate (i.e., the corresponding amounts in 133 mg of the egg-yolk protein hydrolysate).
- the unfractionated egg-yolk protein hydrolysate (1 mg/mL) was used.
- the amino acid sequences of the peptides contained in the fraction with peak 2 were analyzed using MALDI-TOF-MS (mass spectrometer). The analysis results revealed that at least six types of peptides were contained in the fraction with peak 2 as shown in FIG. 8 .
- These peptides are fragments of lipovitellin-1 contained in egg yolk, and each correspond to the following positions in the amino acid sequence of lipovitellin-1 (SEQ ID NO: 8): No. 1 , positions 1045-1052; No. 2 , positions 1045-1051; No. 3 , positions 1047-1051; No. 4 , positions 1053-1059; No. 5 , positions 1052-1059; and No. 6 , positions 1045-1059.
- Example 1 The six types of peptides shown in Example 1 to have osteoblast growth-promoting activity were chemically synthesized and their osteoblast growth-promoting activities were determined.
- the peptide synthesis was performed with a SyroII automatic peptide synthesizer (Biotage Japan Ltd.).
- Osteoblast growth-promoting activity was determined for the synthetic peptides in the same manner as in Example 1.
- the synthetic peptides were added at 2.5, 5 or 10 ⁇ g/mL per well.
- PBS ( ⁇ ) was added.
- the osteoblast growth-promoting activity was expressed in terms of the relative value, with the growth rate in the PBS ( ⁇ ) group taken as 100.
- FIG. 9 shows the results of No. 1
- FIG. 10 shows the results of No. 2 and No. 3
- FIG. 11 shows the results of No. 4 and No. 5
- FIG. 12 shows the results of No. 6 .
- all the synthetic peptides promoted the growth of osteoblasts in a concentration-dependent manner.
- One of the synthetic peptides (No. 1 ) or physiological saline (control) was administered to Sprague-Dawley male rats at three weeks old by oral gavage using a gastric tube once a day for four days.
- the dose of the synthetic peptide was 1, 10 or 100 mg/kg ⁇ day.
- human growth hormone (hGH) (Norditropin, Standard Commodity Classification No. of Japan: 872412) was subcutaneously administered at 20 ⁇ g/k ⁇ day once a day for four days. After the administration on day 4, calcein was subcutaneously administered, and the rats were kept for one day.
- the rats were euthanized by bloodletting under anesthesia, and the tibiae were harvested.
- the tissue specimens of the tibial growth plates were prepared, and calcein deposition areas (fluorescent regions) on the tibial growth plates were measured under a fluorescent microscope to determine the longitudinal bone growth.
- FIG. 13 The results are shown in FIG. 13 .
- the increase in the height of the tibial growth plates was enhanced in a manner consistent with the increase in the dose of the synthetic peptide.
- the effect of enhancing the increase in the height by the synthetic peptide at the highest dose was comparable to the effect of the subcutaneous administration of the human growth hormone.
- ATDC5 mouse-derived chondrogenic cell line ATDC5 (RIKEN BANK, RBC0565).
- ATDC5 cells in the logarithmic growth phase were suspended at 3 ⁇ 10 4 cells/mL in Eagle MEM medium supplemented with 5% FCS (fetal calf serum), and 100 ⁇ L of the cell suspension was seeded in each well of a 96-well plate and precultured at 5% CO 2 and 95% air at 37° C.
- FCS fetal calf serum
- the reaction solution (10 ⁇ g/well) of Cell Counting Kit-8 (Dojindo Laboratories) was added to each well.
- the plate was incubated for 3 hours, and the absorbance at 450 nm was measured with a microplate reader.
- the activity of the synthetic peptides for promoting the growth of chondrocytes was expressed in terms of the relative value, with the absorbance (growth rate) in the control group taken as 100%.
- ATDC5 cells in the logarithmic growth phase were seeded at 2 ⁇ 10 4 cells/mL per well in a 24-well plate containing DMEM/F-12 (1:1) medium supplemented with 5% FCS (fetal calf serum), 10 ⁇ g/mL transferrin and 3 ⁇ 10 ⁇ 8 M sodium selenite.
- FCS fetal calf serum
- the cells were precultured at 5% CO 2 and 95% air at 37° C.
- the medium in each well was removed, and medium containing the synthetic peptide (No. 1 or No. 6 ) at 10 nmol/mL was added.
- the cells were cultured for 72 hours. As a control, medium without a synthetic peptide was added.
- the concentrations of hyaluronic acid in the culture supernatants of the synthetic peptide addition group were calculated by subtracting the absorbance of the background from the absorbance of the supernatants, and fitting the resulting values to the reference curve prepared using the standard.
- Sprague-Dawley male rats at three weeks old were initially fed with a low-calcium diet (containing 0.05% calcium carbonate) for one week, and then fed with a normal diet (containing 1.2% calcium carbonate).
- the synthetic peptide (No. 1 ) or physiological saline (control) was administered to the rats by oral gavage using a gastric tube once a day for seven days.
- the dose of the synthetic peptide was 1, 10 or 100 mg/kg ⁇ day.
- the rats were euthanized by bloodletting under anesthesia, and the femurs and tibiae were harvested.
- the bone volume and bone morphology of the tibiae and femurs were measured by dual energy x-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT). The results revealed that the length, weight, and bone density of the tibiae tended to be higher in the synthetic peptide administration group than in the control group, indicating that the synthetic peptide promoted the recovery of the bone density loss due to calcium deficiency.
- DXA dual energy x-ray absorptiometry
- pQCT peripheral quantitative computed tomography
- OVX ovariectomy
- synthetic peptide No. 1 was administered to the rats by oral gavage using a gastric tube once a day from the first postoperative day for six months.
- the dose of the synthetic peptide was 1, 10 or 100 mg/kg ⁇ day.
- the medium-dose administration group (10 mg/kg ⁇ day) and the high-dose administration group (100 mg/kg ⁇ day) showed an equal or higher bone density as compared with the sham operation group without removal of the ovary.
- the cancellous bone volume in the proximal tibial metaphysis increased in the OVX-synthetic peptide administration group in a manner consistent with the increase in the dose, and the increase was significant as compared with the OVX-control group.
- the medium-dose administration group and the high-dose administration group showed an equal or higher volume of the cancellous bone as compared with the sham operation group without removal of the ovary.
- OVX-induced reduction in the trabecular numbers and the trabecular width and OVX-induced increase in the trabecular separation tended to be inhibited in the OVX-synthetic peptide administration group.
- Synthetic peptide No. 1 was administered to mature female rats (eight months old, ten rats in each group) by oral gavage using a gastric tube once a day for 20 weeks.
- the dose of the synthetic peptide was 1, 10 or 100 mg/kg ⁇ day.
- alendronate sodium hydrate (hereinafter called “alendronate”) (300 ⁇ g/kg) was subcutaneously administered once a day for 20 weeks.
- alendronate alendronate sodium hydrate (hereinafter called “alendronate”) (300 ⁇ g/kg) was subcutaneously administered once a day for 20 weeks.
- the levels of the increases in the synthetic peptide administration group were comparable to those in the alendronate administration group.
- Synthetic peptide No. 1 was administered to aged female rats (13 to 14 months old, ten rats in each group) by oral gavage using a gastric tube once a day for 20 weeks.
- the dose of the synthetic peptide was 1, 10 or 100 mg/kg ⁇ day.
- the alendronate 300 ⁇ g/kg was subcutaneously administered once a day for 20 weeks. The results revealed that the bone density in the femurs and the cancellous bone volume in the proximal tibial metaphysis increased in a dose-dependent manner in the synthetic peptide administration group.
- a crude fraction of osteoclasts was prepared from the long bones and scapulae of rabbits.
- the crude fraction was cultured on dentine slices in the presence of the synthetic peptides (0.0001 to 1000 ⁇ mol/L) for 48 hours, resulting in a reduction in the total area of pits in a concentration-dependent manner.
- Isolated osteoclasts were also prepared by collagen treatment of the crude fraction of osteoclasts.
- the isolated osteoclasts were pretreated with the synthetic peptides (0.0001 to 1000 ⁇ mol/L) for 15 minutes and then cultured on dentine slices for 24 hours, resulting in a reduction in the total area of pits in a concentration-dependent manner.
- Mouse mesenchymal stem cells 10T1/2 (JCRB accession No. JCRB9080) or ST2 (Riken BRC ID: RCB0224) were seeded at 5000 cells/well in a 96-well plate containing DMEM medium supplemented with 10% fetal bovine serum.
- the synthetic peptides were added to the wells at 0.1 to 100 nmol/mL, and the cells were cultured for 72 hours.
- Cell Counting Kit-8 (Dojindo Laboratories) was added at 10 ⁇ L/100 ⁇ L medium, and the plate was incubated at 37° C. for 1 to 4 hours. The absorbance at 450 nm was measured with a microplate reader. The results revealed that the addition of the synthetic peptides significantly increased the growth of 10T1/2 and ST2 cells.
- Mouse mesenchymal stem cells 10T1/2 or ST2 were seeded at 5000 cells/well in a 96-well plate containing DMEM medium supplemented with 10% fetal bovine serum.
- the synthetic peptides were added to the wells at 0.1 to 100 nmol/mL, and the cells were cultured for four days.
- the medium was replaced with DMEM medium supplemented with ⁇ -glycerophosphoric acid I (10 mM) and ascorbic acid (50 ⁇ g/mL). At this medium replacement, medium with or without the synthetic peptides was used for the examination of the effect of their presence.
- the cells were further cultured in the medium for three days (in total, seven days of culture).
- the cells were fixed, and stained for alkaline phosphatase activity using Alkaline Phosphatase Substrate Kit I (VECTOR Red) (Vector Laboratories). The results indicated strong alkaline phosphatase activity in the cells cultured in the presence of the synthetic peptides. The cells cultured in the absence of the synthetic peptides did not show such activity. That is, it was revealed that the addition of the synthetic peptides efficiently induced differentiation of undifferentiated mesenchymal stem cells into osteoblast-like cells (osteogenic cells) over a relatively short period of time of four days.
- Mouse EC (embryonic carcinoma)-derived cloned cell line ATDC5 (Riken BRC ID: RCB0565) with a potential to differentiate into chondrocytes was cultured in DMEM/F-12 medium supplemented with 5% FBS.
- the ATDC cells were seeded at 2 ⁇ 10 4 cells/well in a 48-well plate. After 24 hours of culture, the culture supernatant was removed, then DMEM/F-12 medium supplemented with 10 ng/mL insulin was added, and the synthetic peptides were added at 0.1 to 100 nmol/mL.
- As a positive control 1 and 5 ng/mL BMP-2 or BMP-4 (R&D) was used. The medium was changed every 3 to 4 days.
- mice chondrogenic cells ATDC5 formed Alcian-blue-positive nodules by addition of the synthetic peptides, and the number of the nodules increased in a concentration-dependent manner. This fact indicated that the synthetic peptides induced the differentiation of the ATDC5 cells into chondrocytes. The synergistic effect with BMP-2 or BMP-4 was also indicated.
- Mouse osteoblast-like cell line MC3T3-E1 Subclone-4 (ATCC No. CRL-2593) was cultured at 5% CO 2 and 95% air at 37° C. for 72 hours in 10% FBS-containing ⁇ -MEM medium with the addition of the synthetic peptides at 2.5, 5, or 10 ⁇ g/mL. After the end of culture, the alkaline phosphatase (ALP) activity of the osteoblast-like cells was measured by the p-nitrophenyl phosphate substrate method. The levels of osteocalcin (OCN) in the culture supernatants were determined by ELISA using an osteocalcin measurement kit (Takara Bio).
- ALP activity and the OCN level had a tendency to increase depending on the concentration of the synthetic peptides added.
- ALP and OCN are considered to be the factors reflecting bone formation function, and thus the results suggested that the synthetic peptides promote the bone formation function of osteoblast-like cells via such related factors.
- the dose of the synthetic peptide (No. 1 ) was 100 mg/kg ⁇ day.
- human growth hormone (hGH) (Norditropin, Standard Commodity Classification No. of Japan: 872412) was subcutaneously administered at 500 ⁇ g/kg ⁇ day once a day for seven days.
- tetracycline (20 mg/kg) was subcutaneously administered on day 4 after the administration of the peptide or control, and then calcein (10 mg/kg) was subcutaneously administered on day 6 after the administration of the peptide or control.
- the rats were kept under fasting conditions. Twenty-four hours later, the blood was collected. The rats were then euthanized by bloodletting under anesthesia, and the tibiae were harvested (see FIG. 16 ).
- Non-decalcified specimens of the proximal tibiae were prepared and photographed under a fluorescent microscope (BX-53, OLYMPUS).
- the bone morphology was measured using a morphometry system (Histometry RT digitizer, System Supply Co., Ltd.) and an analysis software (CSS-840 cancellous bone morphometry version, System Supply Co., Ltd.).
- the longitudinal growth rate (Lo.G.R.) in the growth cartilage which is the increase in the height per day, was determined by measuring the distance between the tetracycline label and the calcein label, and dividing the distance by the administration interval between the fluorescent labels (two days).
- the No. 1 administration group also showed a high frequency of incorporation of the fluorescent labels into the primary cancellous bone as compared with the control group and the hGH administration group, suggesting that the synthetic peptide induced fast formation of the cancellous bone in the growth phase ( FIG. 18 , white region).
- IGF-1 insulin-like growth factor
- the dose of the synthetic peptide was 100 mg/kg ⁇ day.
- human growth hormone (hGH) (Norditropin, Standard Commodity Classification No. of Japan: 872412) was subcutaneously administered at 500 ⁇ g/kg ⁇ day once a day for 21 days.
- tetracycline (20 mg/kg) was subcutaneously administered on day 18 after the administration of the peptide or control, and then calcein (10 mg/kg) was subcutaneously administered on day 20 after the administration of the peptide or control. After the administration of the test sample on day 21, the rats were kept under fasting conditions.
- the longitudinal growth rate (Lo.G.R.) in the epiphyseal cartilage which is the increase in the height per day, was determined by measuring the distance between the tetracycline label and the calcein label, and dividing the distance by the administration interval between the fluorescent labels (two days).
- the No. 1 administration group also showed a high percentage of the bone surface occupied by osteoblasts relative to the total bone surface (osteoblast surface/bone surface (Ob.S/BS)) ( FIG. 23 ) and a low percentage of the bone surface occupied by osteoclasts relative to the total bone surface (osteoclast surface/Bone surface (Oc.S/BS)) ( FIG. 24 ).
- the dose of the synthetic peptide was 1, 10 or 100 mg/kg ⁇ day.
- human growth hormone (hGH) (Norditropin, Standard Commodity Classification No. of Japan: 872412) was subcutaneously administered at 500 ⁇ g/kg ⁇ day once a day for seven days.
- tetracycline (20 mg/kg) was subcutaneously administered on day 4 after the administration of the peptide or control, and then calcein (10 mg/kg) was subcutaneously administered on day 6 after the administration of the peptide or control.
- the rats were kept under fasting conditions. Twenty-four hours later, the rats were euthanized by bloodletting under anesthesia, and the tibiae were harvested. Non-decalcified specimens of the proximal tibiae were prepared and photographed under a fluorescent microscope (BX-53, OLYMPUS).
- the bone morphology was measured using a morphometry system (Histometry RT digitizer, System Supply Co., Ltd.) and an analysis software (CSS-840 cancellous bone morphometry version, System Supply Co., Ltd.).
- the mineral apposition rate (MAR), per day, in the secondary cancellous bone was determined by measuring the distance between the tetracycline label and the calcein label in the secondary cancellous bone, and dividing the distance by the administration interval between the fluorescent labels (two days). The results revealed a significant increase in the mineral apposition rate in the hGH administration group and the No. 1 administration group as compared with the control group.
- the No. 1 administration group also showed a significant increase in the mineral apposition rate at a dose of 10 mg/kg ⁇ day or more as compared with the hGH administration group ( FIG. 26 ).
- the No. 1 administration group also showed a high percentage of the bone surface occupied by osteoblasts relative to the total bone surface (osteoblast surface/bone surface (Ob.S/BS)) ( FIG. 27 ) and a high number of osteoblasts relative to the bone tissue volume (number of osteoblasts/tissue volume (N.Ob/TV)) ( FIG. 28 ).
- the increase in the mineral apposition rate in the secondary cancellous bone in the No. 1 administration group would have resulted from the increase in the number of osteoblasts.
- the bone formation rate calculated as the annual fractional volume of bone formed relative to the bone surface resulted in high rates in the No. 1 administration group ( FIG. 29 ).
- the No. 1 administration group also showed a significant increase in the bone formation rate at a dose of 10 mg/kg ⁇ day or more as compared with the control group.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cosmetics (AREA)
Abstract
The present invention provides a novel peptide having bone formation-promoting effect and chondrocyte growth-promoting effect, in particular, a peptide having osteoblast growth-promoting activity, having 100 amino acid residues or less comprising an amino acid sequence selected from
-
- (b) an amino acid sequence derived from the amino acid sequence (a) by conservative substitution or deletion of 1 to 3 amino acids, and
- (c) an amino acid sequence consisting of at least four contiguous amino acids of the amino acid sequence (a) or (b), or
- a derivative thereof or a salt thereof.
Description
- The present invention relates to a peptide having osteoblast growth-promoting activity; a bone formation promoter, a bone resorption inhibitor, a chondrocyte growth promoter, a hyaluronic acid production promoter, a chondrogenic cell differentiation inducer, a mesenchymal stem cell growth promoter and a mesenchymal stem cell differentiation inducer, each comprising the peptide; and use thereof.
- Osteoporosis is a systemic disease that develops due to reduction of the bone volume or the bone mineral content and causes the breakage of the fine structure of bone, which reduces the bone strength and increases the risk of bone fracture. The number of patients with osteoporosis in Japan reaches about 11 million, and 80% of them are women. Osteoporosis mainly affects people in their middle or older age, and considering that the society is aging, the number of patients is expected to increase in the future. Another concern is that the incidence of bone fracture is increasing in elementary and junior high school students. In order to prevent osteoporosis, it is very important to substantially increase the bone mineral content during the young age, thus achieving a high peak bone mass. Thus the maintenance of bone health is now a social interest regardless of sex and age.
- Bone diseases are conventionally prevented or treated by dietary calcium supplementation, light exercise, sun bath, medication, etc. Such dietary calcium supplementation is done with calcium salts such as calcium carbonate and calcium phosphate, and natural calcium sources such as bovine bone powder, egg shells and fish bone powder. However, such ingredients are not very suitable for oral ingestion in terms of solubility, absorptivity and taste. Moderate exercise increases the bone volume and strengthens bone, and a stroll and a walk are good for bone health. However, for people with low physical strength, even light exercise is troublesome, and exercise is almost impossible for the bedridden elderly. Sun bath is considered to be good for supply of activated vitamin D3, but sun bath is insufficient for prevention or treatment of bone diseases.
- For the prevention or treatment of various chondropathies, the growth of chondrocytes and the expression of differentiation function are important. That is, the growth and maturation of chondrocytes are considered to promote normal growth of bone and repair bone fracture. Several factors for inducing the growth of chondrocytes have been reported, including transforming growth factor (TGF)-β1, insulin-like growth factor (IGF)-1, basic fibroblast growth factor (bFGF), PTH-related peptide (PTHrP), hepatocyte growth factor (HGF), and bone morphogenetic protein (BMP). However, clinical applications of chondrocyte growth-promoting drugs excellent in safety, stability and efficacy have not been established yet.
- Patients with osteoarthritis account for the largest proportion of chondropathy patients. One of the causes of osteoarthritis may be aging, and the incidence of the disease is expected to increase in this aging society. Conventionally, bone resorption inhibitors such as estrogen and calcitonin, aspirin, and nonsteroidal anti-inflammatory drugs (NSAIDs) have mostly been used for the prevention and treatment of cartilage disorders that manifest degeneration of cartilage as major symptoms, such as joint diseases. However, these drugs are not effective enough, and are well-known to cause adverse reactions such as digestive tract disorders. Under these circumstances, there has been a great demand for prophylactic or alleviating drugs that are safe for use in the treatment of cartilage injuries and cartilage disorders.
- The inventors found that an egg yolk-derived peptide comprising an amino acid sequence comprising at least Ala-Glu-Ser has osteoblast growth-promoting activity (see Patent Literature 1) and that an egg-yolk protein hydrolysate has chondrocyte growth-promoting activity (see Patent Literature 2). The inventors then filed a patent based on these findings.
- Patent Literature 1: JP 2011-211979 A
- Patent Literature 2: WO 2014/007318
- An object of the present invention is to provide a novel peptide having bone formation-promoting effect and chondrocyte growth-promoting effect and to provide excellent applications of the peptide.
- Solution to Problem
- The present invention has been made to solve the above problems and includes the following.
- [1] A peptide having osteoblast growth-promoting activity, having 100 amino acid residues or less comprising an amino acid sequence selected from
- (a) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu-Asp-Glu-Ser-Ser-Pro-Tyr-Glu (SEQ ID NO: 1),
- (b) an amino acid sequence derived from the amino acid sequence (a) by conservative substitution or deletion of 1 to 3 amino acids, and
- (c) an amino acid sequence consisting of at least four contiguous amino acids of the amino acid sequence (a) or (b), or
- a derivative thereof or a salt thereof.
- [2] The peptide of the above [1] or a derivative thereof or a salt thereof, which has at least one phosphorylated serine.
- [3] The peptide of the above [1] or [2] or a derivative thereof or a salt thereof, which is a fragment of lipovitellin-1.
- [4] The peptide of any one of the above [1] to [3] or a derivative thereof or a salt thereof, which further has chondrocyte growth-promoting activity and/or hyaluronic acid production-promoting activity.
- [5] The peptide of any one of
claims 1 to 4 or a derivative thereof or a salt thereof, which consists of an amino acid sequence selected from -
(i) (SEQ ID NO: 1) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu-Asp-Glu-Ser-Ser-Pro- Tyr-Glu, (ii) (SEQ ID NO: 2) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu, (iii) (SEQ ID NO: 3) Val-Asn-Pro-Glu-Ser-Glu-Glu, (iv) (SEQ ID NO: 4) Pro-Glu-Ser-Glu-Glu, (v) (SEQ ID NO: 5) Asp-Glu-Ser-Ser-Pro-Tyr-Glu, and (vi) (SEQ ID NO: 6) Glu-Asp-Glu-Ser-Ser-Pro-Tyr-Glu. - [6] A polynucleotide encoding the peptide of any one of the above [1] to [5].
- [7] An expression vector comprising the polynucleotide of the above [6].
- [8] A transformant resulting from transformation with the recombinant vector of the above [7].
- [9] A bone formation promoter comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- [10] The bone formation promoter of the above [9], which has osteoblast growth-promoting effect.
- [11] A bone resorption inhibitor comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- [12] A chondrocyte growth promoter comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- [13] A hyaluronic acid production promoter comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- [14] A chondrogenic cell differentiation inducer comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- [15] A mesenchymal stem cell growth promoter comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- [16] A mesenchymal stem cell differentiation inducer comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- [17] The promoter, inhibitor or inducer of any one of the above [9] to [16], which is for oral administration.
- [18] A medicament comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- [19] The medicament of the above [18], for promoting bone formation or for preventing or alleviating a cartilage disorder or a joint disease.
- [20] A food or drink product comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- [21] The food or drink product of the above [20], for promoting bone formation or for preventing or alleviating a cartilage disorder or a joint disease.
- [22] A supplement comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- [23] The supplement of the above [22], for promoting bone formation or for preventing or alleviating a cartilage disorder or a joint disease.
- [24] A food additive comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- [25] The food additive of the above [24], for promoting bone formation or for preventing or alleviating a cartilage disorder or a joint disease.
- [26] A cosmetic product comprising the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- [27] The cosmetic product of the above [26], for promoting bone formation or for preventing or alleviating a cartilage disorder or a joint disease.
- [28] A method for promoting bone formation, the method comprising administering, to a mammal, an effective amount of the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- [29] A method for preventing or alleviating a cartilage disorder or a joint disease, the method comprising administering, to a mammal, an effective amount of the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- [30] The peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof for use in the promotion of bone formation or the prevention or alleviation of a cartilage disorder or a joint disease.
- [31] Use of the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof for the promotion of bone formation or for the prevention or alleviation of a cartilage disorder or a joint disease.
- [32] Use of the peptide of any one of the above [1] to [5] or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof for the production of a medicament for promoting bone formation or for preventing or alleviating a cartilage disorder or a joint disease.
- The present invention provides a novel peptide having bone formation-promoting effect and chondrocyte growth-promoting effect. The peptide can promote bone formation via oral ingestion, and is thus useful as a medicament, a food or drink product, a supplement, a food additive, a cosmetic product, etc. that are for promoting bone formation or for preventing or alleviating a cartilage disorder or joint pain.
-
FIG. 1 shows a chart showing the measurement results of the osteoblast growth-promoting activity of fractions resulting from fractionation of an egg-yolk protein hydrolysate with a UF membrane with a cut-off molecular weight of 1 kDa. -
FIG. 2 shows a chart showing the measurement results of the osteoblast growth-promoting activity of a non-adsorbed fraction (flow-through) and fractions eluted with sodium chloride solutions at concentrations of 750 mM and 1 M from an anion-exchange column loaded with a fraction with a molecular weight of 1 kDa or more obtained from the egg-yolk protein hydrolysate. -
FIG. 3 is a chart showing fractions resulting from reverse-phase HPLC fractionation of the 750 mM NaCl eluate fraction, which showed high osteoblast growth-promoting activity. -
FIG. 4 is a chart showing the measurement results of the osteoblast growth-promoting activity of G1 to G9 indicated inFIG. 3 . -
FIG. 5 is a chart showing the measurement results of the osteoblast growth-promoting activity offractions 11 to 20 contained in G3 and G4. -
FIG. 6 is a chart showing peaks detected infraction 12 by HPLC under conditions different from those of the above HPLC. -
FIG. 7 is a chart showing the measurement results of the osteoblast growth-promoting activity of fractions with the two peaks indicated inFIG. 6 . -
FIG. 8 shows the analysis results of the structure of peptides. -
FIG. 9 is a chart showing the measurement results of the osteoblast growth-promoting activity of a synthetic peptide (No. 1). -
FIG. 10 is a chart showing the measurement results of the osteoblast growth-promoting activity of synthetic peptides (No. 2 and No. 3). -
FIG. 11 is a chart showing the measurement results of the osteoblast growth-promoting activity of synthetic peptides (No. 4 and No. 5). -
FIG. 12 is a chart showing the measurement results of the osteoblast growth-promoting activity of a synthetic peptide (No. 6). -
FIG. 13 is a chart showing the measurement results of the increased height of the tibial growth plates of rats after oral administration of a synthetic peptide (No. 1). -
FIG. 14 is a chart showing the measurement results of the chondrocyte growth-promoting activity of synthetic peptides (No. 1 and No. 6). -
FIG. 15 is a chart showing the measurement results of the hyaluronic acid production-promoting activity of synthetic peptides (No. 1 and No. 6). -
FIG. 16 shows the experimental protocol of Example 14. -
FIG. 17 is a chart showing the measurement results of the growth rate of the growth cartilage per day (in the longitudinal direction) in a synthetic peptide administration group. -
FIG. 18 shows fluorescent microscope images of the formation of primary cancellous bone in a synthetic peptide administration group. -
FIG. 19 is a chart showing an increase in the serum level of insulin-like growth factor (IGF-1) in a synthetic peptide administration group. -
FIG. 20 shows the experimental protocol of Example 15. -
FIG. 21 is a chart showing the calculation results of the increased height of the rat tibiae per day in a synthetic peptide administration group. -
FIG. 22 is a chart showing the measurement results of the secondary cancellous bone volume relative to the bone tissue volume in rats in a synthetic peptide administration group. -
FIG. 23 is a chart showing the measurement results of the percentage of the bone surface occupied by osteoblasts relative to the total bone surface in a synthetic peptide administration group. -
FIG. 24 is a chart showing the measurement results of the percentage of the bone surface occupied by osteoclasts relative to the total bone surface in a synthetic peptide administration group. -
FIG. 25 shows the experimental protocol of Example 16. -
FIG. 26 is a chart showing the calculation results of the mineral apposition rate, per day, in the secondary cancellous bone of rats in a synthetic peptide administration group. -
FIG. 27 is a chart showing the measurement results of the percentage of the bone surface occupied by osteoblasts relative to the total bone surface in a synthetic peptide administration group. -
FIG. 28 is a chart showing the measurement results of the number of osteoblasts relative to the bone tissue volume in rats in a synthetic peptide administration group. -
FIG. 29 is a chart showing the calculation results of the bone formation rate in a synthetic peptide administration group. - Peptides
- The present invention provides a peptide having osteoblast growth-promoting activity.
- The inventors investigated the identification of peptides with strong activity for promoting the growth of osteoblasts from a peptide mixture obtained by hydrolysis of egg yolk proteins, and isolated the peptides consisting of the amino acid sequences (i) to (vi) shown below. The amino acid sequences (ii) to (vi) are partial sequences of the amino acid sequence (i).
-
(i) (SEQ ID NO: 1) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu-Asp-Glu-Ser-Ser-Pro- Tyr-Glu (ii) (SEQ ID NO: 2) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu (iii) (SEQ ID NO: 3) Val-Asn-Pro-Glu-Ser-Glu-Glu (iv) (SEQ ID NO: 4) Pro-Glu-Ser-Glu-Glu (v) (SEQ ID NO: 5) Asp-Glu-Ser-Ser-Pro-Tyr-Glu (vi) (SEQ ID NO: 6) Glu-Asp-Glu-Ser-Ser-Pro-Tyr-Glu - The peptide provided by the present invention is a peptide having osteoblast growth-promoting activity, comprising an amino acid sequence selected from
-
(a) (SEQ ID NO: 1) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu-Asp-Glu-Ser-Ser- Pro-Tyr-Glu, - (b) an amino acid sequence derived from the amino acid sequence (a) by conservative substitution or deletion of 1 to 3 amino acids, and
- (c) an amino acid sequence consisting of at least four contiguous amino acids of the amino acid sequence (a) or (b).
- The peptide of the present invention may be a peptide consisting of the amino acid sequence (a), (b) or (c), or a peptide comprising the amino acid sequence (a), (b) or (c) and an amino acid sequence other than (a), (b) or (c). In cases where the peptide of the present invention comprises an amino acid sequence other than (a), (b) or (c), the amino acid sequence other than (a), (b) or (c) is not particularly limited as long as the peptide retains osteoblast growth-promoting activity. The amino acid sequence other than (a), (b) or (c) may be, for example, a tag sequence (e.g., a polyhistidine tag, a Myc tag, a FLAG tag, etc.).
- The number of the amino acid residues contained in the peptide of the present invention is not particularly limited, but is preferably 1000 or less, more preferably 500 or less, further more preferably 200 or less, further more preferably 100 or less, further more preferably 80 or less, further more preferably 70 or less, further more preferably 60 or less, further more preferably 50 or less, further more preferably 40 or less, further more preferably or less, further more preferably 20 or less, particularly preferably 15 or less. The minimum number of the amino acid residues is not particularly limited as long as the peptide retains osteoblast growth-promoting activity, but the minimum number of the amino acid residues is preferably 3 or more, more preferably 4 or more, further more preferably 5 or more.
- A homology search revealed that the amino acid sequence of SEQ ID NO: 1 corresponds to positions 1060 to 1074 of the amino acid sequence of vitellogenin-2 (SEQ ID NO: 7), which is a precursor protein contained in an egg yolk. The peptide of the present invention is, hence, preferably a fragment of vitellogenin-2 that contains at least four contiguous amino acids at positions 1060 to 1074 of vitellogenin-2 and has osteoblast growth-promoting activity.
- Vitellogenin-2 is a precursor protein contained in an egg yolk, and is known to be cleaved into four yolk proteins: lipovitellin-1, phosvitin, lipovitellin-2 and YGP40 (yolk glycoprotein of 40 kDa) (see the database UniProt: P02845 (VIT2 CHICK)). Positions 1060 to 1074 of vitellogenin-2 corresponds to positions 1045 to 1059 of the amino acid sequence of lipovitellin-1 (SEQ ID NO: 8). The peptide of the present invention is, hence, preferably a fragment of lipovitellin-2 that contains at least four contiguous amino acids at positions 1045 to 1059 of lipovitellin-1 and has osteoblast growth-promoting activity.
- Preferably, the peptide of the present invention is a peptide consisting of any of the amino acid sequences (i) to (vi).
- The term “conservative substitution of amino acids” herein means substitution of an amino acid for another one within the same group shown in Table 1 below. In Table 1, preferred conservative substitutions of amino acids include a substitution between aspartic acid and glutamic acid, a substitution among arginine, lysine, and histidine, a substitution between tryptophan and phenylalanine, a substitution between phenylalanine and valine, a substitution among leucine, isoleucine and alanine, and a substitution between glycine and alanine.
-
TABLE 1 Acidic amino acids Aspartic acid (D), glutamic acid (E) Basic amino acids Arginine (R), lysine (K), histidine (H) Hydrophilic amino Serine (S), threonine (T), asparagine (N), acids glutamine (Q) Hydrophobic amino Tryptophan (W), phenylalanine (F), valine (V), acids leucine (L), isoleucine (I), methionine (M), proline (P), alanine (A) Aromatic amino acids Tyrosine (Y), tryptophan (W), phenylalanine (F) Hydroxyamino acids Serine (S), threonine (T) Sulfur-containing Cysteine (C), cystine, methionine (M) amino acids Small amino acids Glycine (G), alanine (A), serine (S), methionine (M), threonine (T) - The peptide derivative of the present invention is derived from a peptide with a particular amino acid sequence and the C-terminus of the peptide derivative may be a carboxyl group (—COOH), a carboxylate (—COO−), an amide (—CONH2) or an ester (—COOR). Examples of R of the ester include C1-6 alkyl groups such as methyl, ethyl, n-propyl, isopropyl and n-butyl; C3-8 cycloalkyl groups such as cyclopentyl and cyclohexyl; C6-12 aryl groups such as phenyl and α-naphthyl; C7-14 aralkyl groups including phenyl-C1-2 alkyl groups, such as benzyl and phenethyl, and α-naphthyl-C1-2 alkyl groups, such as α-naphthylmethyl; and a pivaloyloxymethyl group, which is commonly used as an ester for oral administration. Examples of the amide include an amide; an amide substituted with one or two C1-6 alkyl groups; an amide substituted with one or two C1-6 alkyl groups substituted with a phenyl group; and an amide that forms a 5- to 7-membered azacycloalkane containing the nitrogen atom of the amide group. When the peptide of the present invention has a carboxyl group or a carboxylate at a position other than the C-terminus, those with amidated or esterified carboxyl or carboxylate are also included in the peptide derivative of the present invention.
- The peptide derivative of the present invention also includes the peptides of the present invention in which the N-terminal amino group is protected with a protecting group (e.g., a C1-6 acyl group including a formyl group and C2-6 alkanoyl groups such as acetyl), the peptides of the present invention in which a N-terminal glutamyl group generated by in vivo cleavage of the N-terminus is converted to a pyroglutamate, and the peptides of the present invention in which a substituent (e.g., —OH, —SH, an amino group, an imidazole group, an indole group, or a guanidino group) on an amino acid side chain in the molecule is protected with a suitable protecting group (e.g., a C1-6 acyl group including a formyl group and C2-6 alkanoyl groups such as acetyl).
- The side chains of the amino acids constituting the peptide derivative of the present invention may be modified with a substituent. Examples of the substituent include, but are not limited to, a fluorine atom, a chlorine atom, a cyano group, a hydroxy group, a nitro group, an alkyl group, a cycloalkyl group, an alkoxy group, an amino group, and a phosphate group. The side-chain substituent may be protected with a protecting group. The derivative of the peptide of the present invention also includes glycopeptides, which are peptides having sugar chains.
- The peptide of the present invention or a derivative thereof may form a salt. The salt is preferably physiologically acceptable. Examples of the physiologically acceptable salt include salts with acids such as hydrochloric acid, sulfuric acid, phosphoric acid, lactic acid, tartaric acid, maleic acid, fumaric acid, oxalic acid, malic acid, citric acid, oleic acid, and palmitic acid; salts with hydroxides or carbonates of an alkali metal, such as sodium, potassium and calcium, salts with hydroxides or carbonates of an alkaline earth metal, and salts with aluminum hydroxide or carbonate; and salts with triethylamine, benzylamine, diethanolamine, t-butylamine, dicyclohexylamine, arginine, etc.
- The peptide of the present invention or a derivative thereof may comprise a D-amino acid or a non-naturally occurring amino acid to the extent that the peptide or derivative retains its characteristics. The peptide of the present invention or a derivative thereof may comprise another substance linked thereto to the extent that the peptide or derivative retains its characteristics. Examples of the substance linkable to the peptide include other peptides, lipids, sugars, sugar chains, an acetyl group, and naturally occurring or synthetic polymers. The peptide of the present invention may be subjected to modification such as glycosylation, side-chain oxidation, and phosphorylation to the extent that the resulting modified peptide retains the characteristics of the original peptide.
- The peptide of the present invention or a derivative thereof or a salt thereof preferably has at least one phosphorylated serine. The position of the phosphorylated serine is not particularly limited, but preferably at least one of the serine residues at
positions positions positions - Preferred peptide derivatives of the present invention are peptides with a phosphorylated serine residue represented by the amino acid sequences of SEQ ID NOs: 9 to 14 (see
FIG. 10 ). - The peptide of the present invention or a derivative thereof or a salt thereof (hereinafter the peptide, the derivative and the salt are collectively and simply called “the peptide of the present invention”) can be produced by solid-phase synthesis (the Fmoc or Boc method) or liquid-phase synthesis in accordance with a known standard peptide synthesis protocol. Alternatively, the peptide of the present invention can be produced by using a transformant carrying an expression vector containing a DNA encoding the peptide of the present invention. Alternatively, the peptide of the present invention can be produced by preparing a peptide using a transformant carrying an expression vector containing a DNA encoding a peptide comprising the peptide of the present invention, and cleaving the resulting peptide with a suitable protease or peptidase. Alternatively, the peptide of the present invention can be produced by a method using an in vitro transcription-translation system.
- The peptide of the present invention can be obtained by purifying a hydrolysate of chicken egg yolk proteins. The preparation method of a hydrolysate of egg yolk proteins and the purification method of the peptide are not particularly limited, and the preparation and purification may be done by a known method selected as appropriate. Specifically, the peptide can be obtained by, for example, preparing a defatted egg yolk powder, then preparing a hydrolysate from the powder using an enzyme such as a protease, and purifying a peptide of interest from the hydrolysate by ultrafiltration or chromatography such as HPLC.
- Whether the peptide of interest has osteoblast growth-promoting activity can be determined by comparing the growth of osteoblasts between the culture in the presence of the peptide and the culture in the absence of the peptide in a test system selected as appropriate from known methods for measuring the cell growth. A higher growth level of osteoblasts in the culture in the presence of the peptide indicates that the peptide has the promoting activity. Specifically, for example, MTT assay or cell counting method may be performed in a cell culture system
- Whether the peptide of interest has chondrocyte growth-promoting activity can be determined by comparing the growth of chondrocytes or chondrogenic cells between the culture in the presence of the peptide and the culture in the absence of the peptide in a test system selected as appropriate from known methods for measuring the cell growth. A higher growth level of osteoblasts in the culture in the presence of the peptide indicates that the peptide has the promoting activity. Specifically, for example, MTT assay or cell counting method may be performed in a cell culture system using an osteoblast-derived cell line.
- Whether the peptide of interest has hyaluronic acid production-promoting activity can be determined by measuring, by a known method, the amounts of hyaluronic acid production in the culture supernatant in culture using cultured cells with an ability to produce hyaluronic acid, and then comparing the amounts of hyaluronic acid between the culture in the presence of the peptide and the culture in the absence of the peptide. A higher amount of hyaluronic acid in the supernatant of the culture in the presence of the peptide indicates that the peptide has the promoting activity. Examples of the measurement method of the amount of hyaluronic acid include ELISA.
- Polynucleotides
- The polynucleotide provided by the present invention is a polynucleotide encoding the above peptide of the present invention. The polynucleotide can be present in the form of RNA (e.g., mRNA) or DNA (e.g., cDNA or genomic DNA). The polynucleotide may be a double or single strand. The double strand may be a double-stranded DNA, a double-stranded RNA or a DNA-RNA hybrid. The single strand may be a coding strand (sense strand) or a non-coding strand (antisense strand). The polynucleotide of the present invention may be fused with a polynucleotide encoding a tag label (a tag sequence or a marker sequence) at the 5′- or 3′-terminus. The polynucleotide of the present invention may contain an untranslated region (UTR) sequence, a vector sequence (including an expression vector sequence), etc.
- The nucleotide sequence of the polynucleotide encoding the peptide of the present invention can be custom designed by appropriately selecting codons for amino acids based on the amino acid sequence of the peptide of the present invention and combining the selected codons. As described above, the amino acid sequence of SEQ ID NO: 1 is part of the amino acid sequence of vitellogenin-2 (SEQ ID NO: 7), which is a precursor protein contained in an egg yolk, and therefore the nucleotide sequence of the polynucleotide can be designed based on the nucleotide sequence of the gene encoding vitellogenin-2.
- The polynucleotide of the present invention can be produced by a known DNA synthesis method, PCR, etc. Specifically, for example, the nucleotide sequence is designed by appropriately selecting codons for amino acids based on the amino acid sequence of the peptide of the present invention, and the designed sequence is chemically synthesized using a commercially available DNA synthesizer. Alternatively, primers are designed for amplification of the coding region of the peptide of the present invention in the nucleotide sequence of the gene encoding vitellogenin-2 (accession No.: X13607), and then PCR etc. are performed with chicken genomic DNA or cDNA as a template using the designed primers to produce a DNA fragment containing the polynucleotide of the present invention in large quantities.
- Expression Vectors
- The present invention provides an expression vector used for the production of the peptide of the present invention. The expression vector of the present invention is not particularly limited as long as it contains a polynucleotide encoding the peptide of the present invention, but preferred are plasmid vectors carrying a RNA polymerase recognition sequence (pSP64, pBluescript, etc.). The method for preparing the expression vector is not particularly limited, and the expression vector may be prepared with the use of a plasmid, a phage, a cosmid or the like. The type of the vector is not particularly limited and any appropriate vector that can be expressed in host cells can be selected. For example, a promoter sequence is selected as appropriate for the type of host cells to ensure the expression of the polynucleotide of the present invention, and this promoter sequence and the polynucleotide of the present invention are inserted into a plasmid etc. to give a desired expression vector. After a host transformed with the expression vector of the present invention is cultured, cultivated or bred, the peptide of the present invention can be collected and purified from the culture products etc. by conventional methods (e.g., filtration, centrifugation, cell disruption, gel filtration chromatography, ion exchange chromatography, etc.).
- The expression vector preferably contains at least one selection marker. Examples of the marker include a dihydrofolate reductase gene and a neomycin resistance gene for eukaryote cell culture; and a tetracycline resistance gene and an ampicillin resistance gene for culture of Escherichia coli and other bacteria. Such a selection marker is useful for checking whether the polynucleotide of the present invention has been successfully transfected into host cells and whether the polynucleotide is reliably expressed therein. Alternatively, the peptide of the present invention may be expressed as a fusion protein. The peptide of the present invention may be expressed as, for example, a GFP fusion protein using green fluorescent protein (GFP) of Aequorea victoria as a marker.
- The host is not particularly limited and various known cells can suitably be used. Specific examples of the cells include bacteria such as Escherichia coli, yeasts (budding yeast Saccharomyces cerevisiae and fission yeast Schizosaccharomyces pombe), nematodes (Caenorhabditis elegans), Xenopus laevis oocytes and animal cells (e.g., CHO cells, COS cells and Bowes melanoma cells). The method for transfecting host cells with the expression vector, i.e. the transformation method, is also not particularly limited and known methods can suitably be used, including electroporation, the calcium phosphate method, the liposome method and the DEAE dextran method.
- Transformants
- The present invention provides a transformant carrying the expression vector of the present invention. As used herein, the transformant encompasses a cell, a tissue and an organ as well as an individual organism. The type of the organism to be transformed is not particularly limited, and examples thereof include various microorganisms, plants and animals listed above as examples of the host cells. The transformant of the present invention expresses the peptide of the present invention. It is preferred that the transformant of the present invention stably expresses the peptide of the present invention, but the transformant may transiently express the peptide.
- Bone Formation Promoter, Bone Resorption Inhibitor, Chondrocyte Growth Promoter, Hyaluronic Acid Production Promoter, Chondrogenic Cell Differentiation Inducer, Mesenchymal Stem Cell Growth Promoter, and Mesenchymal Stem Cell Differentiation Inducer
- The present invention provides a bone formation promoter comprising the peptide of the present invention. Since the peptide of the present invention has bone formation-promoting activity, the peptide is suitable as an active ingredient for a bone formation promoter. The bone formation-promoting activity of the peptide of the present invention can be confirmed by, for example, administering (e.g., oral administering) the peptide of the present invention to an animal subject for a certain period of time (e.g., for 7, 14 or 21 days), and measuring an indicator for the activity, including an enhanced increase in the height of the tibial growth plate, an increase in the growth rate of the growth cartilage, promotion of the formation of the primary cancellous bone, an increase in the serum level of insulin-like growth factor (IGF-1), an increase in the secondary cancellous bone volume relative to the bone tissue volume, an increase of osteoblasts, a reduction of osteoclasts, an increase in the mineral apposition rate in the secondary cancellous bone, etc. The term “growth cartilage” herein refers to, for example, the growing area of the bone at the epiphysis. The term “primary cancellous bone” refers to, for example, immature cancellous bone immediately below the growth cartilage. The term “secondary cancellous bone” refers to, for example, mature cancellous bone. The term “promotion of bone formation” herein can be understood as “an enhanced increase in the height of the tibial growth plate”, “an increase in the growth rate of the growth cartilage”, “promotion of the formation of the primary cancellous bone”, “an increase in the serum level of insulin-like growth factor (IGF-1)”, “an increase in the secondary cancellous bone volume relative to the bone tissue volume”, “an increase of osteoblasts”, “a reduction of osteoclasts”, “an increase in the mineral apposition rate in the secondary cancellous bone”, etc. The present invention also provides an osteoblast growth promotor comprising the peptide of the present invention. Since the peptide of the present invention has osteoblast growth-promoting activity, the peptide is suitable as an active ingredient for an osteoblast growth promotor. The present invention also provides a bone resorption inhibitor comprising the peptide of the present invention. The peptide of the present invention has bone resorption-inhibiting activity, and is thus suitable as an active ingredient for a bone resorption inhibitor. The present invention also provides a chondrocyte growth promotor comprising the peptide of the present invention. Since the peptide of the present invention has chondrocyte growth-promoting activity, the peptide is suitable as an active ingredient for a chondrocyte growth promoter. The present invention also provides a hyaluronic acid production promoter comprising the peptide of the present invention. Since the peptide of the present invention has hyaluronic acid production-promoting activity, the peptide is suitable as an active ingredient for a hyaluronic acid production promoter. The present invention also provides a chondrogenic cell differentiation inducer comprising the peptide of the present invention. Since the peptide of the present invention has differentiation inducing activity on chondrogenic cells, the peptide is suitable as an active ingredient for a chondrogenic cell differentiation inducer. The present invention also provides a mesenchymal stem cell growth promoter comprising the peptide of the present invention. The peptide of the present invention has growth-promoting activity on mesenchymal stem cells, and is thus suitable as an active ingredient for a mesenchymal stem cell growth promoter. The present invention also provides a mesenchymal stem cell differentiation inducer comprising the peptide of the present invention. The peptide of the present invention has differentiation inducing activity on mesenchymal stem cells, and is thus suitable as an active ingredient for a mesenchymal stem cell differentiation inducer.
- In addition to the peptide of the present invention, lipovitellin-1 or a derivative thereof or a salt thereof is also suitable as an active ingredient for the above promoter, inhibitor or inducer. The lipovitellin-1 herein refers to a protein that consists of an amino acid sequence identical or substantially identical to the amino acid sequence of SEQ ID NO: 8 and has substantially the same activity as that of lipovitellin-1. The amino acid sequence substantially identical to the amino acid sequence of SEQ ID NO: 8 is, for example, an amino acid sequence derived from SEQ ID NO: 8 by deletion, substitution or addition of one to several amino acids. The phrase “deletion, substitution or addition of one to several amino acids” means deletion, substitution or addition of amino acids whose number is substantially equal to the number of the residues that can be deleted, substituted or added by a known method for mutagenesis of peptides, such as site-directed mutagenesis (preferably 10 amino acids or less, more preferably 7 amino acids or less, and even more preferably 5 amino acids or less). Such a mutant protein is not limited to a protein artificially mutated by a known method for mutagenesis of polypeptides, and may be a protein isolated and purified from nature. In addition, the amino acid sequence substantially identical to the amino acid sequence of SEQ ID NO: 1 is, for example, an amino acid sequence that is at least 80% identical, more preferably at least 85%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 1.
- A derivative of lipovitellin-1 is preferably those listed above as the examples of the derivative of the peptide of the present invention. A salt of lipovitellin-1 or of a derivative of lipovitellin-1 is preferably those listed above as the examples of the salt of the peptide of the present invention or of the derivative of the peptide of the present invention.
- Lipovitellin-1, a derivative thereof and a salt thereof can be produced as a recombinant protein by known genetic modification techniques or by methods using in vitro transcription-translation system. Alternatively, lipovitellin-1, a derivative thereof and a salt thereof can be purified from chicken egg yolk proteins.
- Hereinafter, the term “peptide etc. of the present invention” encompasses lipovitellin-1, a derivative thereof and a salt thereof in addition to “the peptide of the present invention”.
- The peptide etc. of the present invention have been shown to exhibit the desired effects through oral administration to a mammal, and thus the above promoters, inhibitors and inducers are suitable for oral administration. The peptide etc. of the present invention, which are the egg yolk protein lipovitellin-1 or a fragment thereof, are highly safe and have mild effects, and thus can be administered or used for a long period of time.
- Medicaments
- The present invention provides a medicament comprising the peptide etc. of the present invention. Since the peptide etc. of the present invention have osteoblast growth-promoting activity, the peptide etc. can be used as a medicament for promoting bone formation. The medicament for promoting bone formation of the present invention can be suitable as a medicament for preventing or treating, for example, osteoporosis, osteogenesis imperfecta, hypercalcemia, hyperparathyroidism, osteomalacia, osteohalisteresis, osteolytic bone disease, osteonecrosis, Paget's disease, rheumatoid arthritis, bone loss due to osteoarthritis, inflammatory arthritis, osteomyelitis, glucocorticoid treatment, metastatic bone disease, periodontal bone loss, cancerous bone loss, age-related bone loss, fracture, and low back pain.
- Since the peptide etc. of the present invention have chondrocyte growth-promoting activity and/or hyaluronic acid production-promoting activity, the peptide etc. can be used as a medicament for preventing or alleviating a cartilage disorder or a joint disease. Examples of the cartilage disorder include osteoarthritis, cartilage defects, cartilage injury, and meniscus injury. Examples of the joint disease include joint pain, rheumatoid arthritis, osteoarthritis, suppurative arthritis, gouty arthritis, traumatic arthritis, and degenerative joint disease.
- The medicament of the present invention can be produced by appropriately blending the peptide etc. of the present invention as an active ingredient with a pharmaceutically acceptable carrier or additive in accordance with a known production method for pharmaceutical preparations (e.g., the methods described in the Japanese pharmacopoeia, etc.). In particular, the medicament may be, for example, an oral preparation or a parenteral preparation, including tablets (including sugar-coated tablets, film-coated tablets, sublingual tablets, orally disintegrating tablets, and buccal tablets), pills, powders, granules, capsules (including soft capsules and microcapsules), troches, syrups, liquids, emulsions, suspensions, controlled-release preparations (e.g., fast-release preparations, sustained release preparations, and sustained release microcapsules), aerosols, films (e.g., orally disintegrating films, and oral mucosal adhesive films), injections (e.g., subcutaneous injections, intravenous injections, intramuscular injections, and intraperitoneal injections), intravenous infusions, transdermal preparations, ointments, lotions, patches, suppositories (e.g., rectal suppositories and vaginal suppositories), pellets, transnasal preparations, transpulmonary preparations (inhalants), and eye drops. The amount of the carrier or additive to be added can be determined as appropriate based on the range typically used in the pharmaceutical field. The carrier or additive that may be added is not particularly limited and examples thereof include various types of carriers such as water, physiological saline, other aqueous solvents, and aqueous or oily vehicles; and various types of additives such as excipients, binders, pH adjusters, disintegrants, absorption promoters, lubricants, colorants, flavors and fragrances.
- Examples of the additives that may be added to tablets, capsules, etc. include binders such as gelatin, corn starch, tragacanth, and gum arabic; excipients such as crystalline cellulose; swelling agents such as corn starch, gelatin, and alginic acid; lubricants such as magnesium stearate; sweeteners such as sucrose, lactose, and saccharin; and flavors such as peppermint flavor, wintergreen oil, and cherry flavor. When the unit dosage form is a capsule, a liquid carrier such as oils and fats can be further added in addition to the above types of materials. A sterile composition for injection can be prepared in accordance with a usual pharmaceutical practice (for example, by dissolving or suspending the active ingredient in a solvent such as water for injection or a natural vegetable oil). Aqueous liquids for injection that may be used are, for example, physiological saline and an isotonic solution containing glucose and/or other auxiliary substances (for example, D-sorbitol, D-mannitol, sodium chloride, etc.). The aqueous liquids for injection may be used in combination with an appropriate solubilizer, such as alcohols (e.g., ethanol), polyalcohols (e.g., propylene glycol, polyethylene glycol, etc.), and nonionic surfactants (e.g.,
polysorbate 80™, HCO-50, etc.). Oily liquids that may be used are, for example, sesame oil and soybean oil. The oily liquids may be used in combination with a solubilizer such as benzyl benzoate and benzyl alcohol. Other additives that may be added are, for example, buffering agents (e.g., a phosphate buffer, a sodium acetate buffer, etc.), soothing agents (e.g., benzalkonium chloride, procaine hydrochloride, etc.), stabilizers (e.g., human serum albumin, polyethylene glycol, etc.), preservatives (e.g., benzyl alcohol, phenol, etc.) and antioxidants. - The preparations produced in the above manner are safe and have low toxicity, and thus can be administered to, for example, humans and other mammals (e.g., rats, mice, rabbits, sheep, pigs, cows, cats, dogs, monkeys, etc.).
- The amount of the peptide etc. of the present invention in the medicament of the present invention may vary with the dosage form, the administration method, the carrier to be used, etc., but is usually 0.01 to 100% (w/w), preferably 0.1 to 95% (w/w), relative to the total amount of the preparation. The medicament of the present invention containing the peptide etc. of the present invention in such an amount can be produced in accordance with a conventional method.
- The dosage varies with the subject to which the medicament is to be administered, the symptom, the route of administration, etc., but in general, the dosage for oral administration to a human with a body weight of about 60 kg is about 0.01 to 1000 mg per day, preferably about 0.1 to 100 mg per day, and more preferably about 0.5 to 500 mg per day. The total daily dosage may be administered in a single dose or in divided doses.
- The medicament of the present invention is expected to exhibit a high additive or synergistic effect in combination with another medicament for treating a bone disease or for treating a cartilage or joint disease. Said another medicament for promoting bone formation may be, for example, an active vitamin D3 preparation, a vitamin K2 preparation, a parathyroid hormone preparation (teriparatide), a female hormone preparation (estrogen), a bisphosphonate preparation, a SERM (raloxifene hydrochloride), a calcitonin preparation, etc. Said another medicament for treating a cartilage or joint disease may be, for example, glucosamine, chondroitin, type I collagen, type II collagen, N-acetylglucosamine, etc.
- Food or Drink Products
- The present invention provides a food or drink product comprising the peptide etc. of the present invention. The food or drink product of the present invention is suitable as a food or drink product for promoting bone formation and as a food or drink product for preventing and/or alleviating a cartilage disorder or a joint disease.
- The food or drink product includes health foods, functional foods, foods for specified health use, and foods for sick people. The form of the food or drink product is not particularly limited and examples thereof include drinks such as tea drink, refreshing drink, carbonated drink, nutritional drink, fruit juice, and lactic drink; noodles such as buckwheat noodle, wheat noodle, Chinese noodle, and instant noodle; sweets and bakery products such as drop, candy, gum, chocolate, snack, biscuit, jelly, jam, cream, pastry, and bread; fishery and livestock products such as fish sausage, ham, and sausage; dairy products such as processed milk and fermented milk; fats, oils, and processed foods thereof, such as vegetable oil, oil for deep frying, margarine, mayonnaise, shortening, whipped cream, and dressing; seasonings such as sauce and dipping sauce; retort pouch foods such as curry, stew, rice-bowl cuisine, porridge, and rice soup; and frozen desserts such as ice cream, sherbet, and shaved ice.
- The present invention also provides a supplement comprising the peptide etc. of the present invention. The supplement of the present invention is suitable as a supplement for promoting bone formation and as a supplement for preventing and/or alleviating a cartilage disorder or a joint disease. The supplement can be provided in the form of, for example, tablets, granules, powders or drinks.
- The present invention provides a food additive comprising the peptide etc. of the present invention. The food additive of the present invention is suitable as a food additive for promoting bone formation and as a food additive for preventing and/or alleviating a cartilage disorder or a joint disease. The form of the food additive of the present invention is not particularly limited, and may be, for example, a liquid, a paste, a powder, flakes, granules, etc. The food additive of the present invention can be produced in accordance with a conventional production method for food additives.
- Also provided is a feed or a feed additive comprising the peptide etc. of the present invention.
- The present invention provides a cosmetic product comprising the peptide etc. of the present invention. The cosmetic product of the present invention is suitable as a cosmetic product for promoting bone formation and as a cosmetic product for preventing and/or alleviating a cartilage disorder or a joint disease. The cosmetic product includes the so-called medicated cosmetics (quasi drugs). Examples of the cosmetic product include washing lotions, shampoos, rinses, hair tonics, hair lotions, aftershave lotions, body lotions, makeup lotions, cleansing creams, massage creams, emollient creams, aerosol products, deodorizers, fragrances, deodorants, and bath fragrances. Depending on the purpose, the cosmetic product of the present invention may contain a component generally used in cosmetic products in addition to the peptide of the present invention, and such a component includes, for example, surfactants, moisturizers, animal- and plant-derived fats and oils, silicones, higher alcohols, lower alcohols, animal- and plant-derived extracts, ultraviolet absorbers, anti-inflammatories, sequestering agents, vitamins, antioxidants, thickeners, preservatives, bactericides, pH adjusters, colorants, and various fragrances.
- The present invention further includes the following.
- (a) Use of the peptide of the present invention or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof for the production of a medicament for promoting bone formation or for preventing or alleviating a cartilage disorder or a joint disease.
- (b) The peptide of the present invention or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof for use in the promotion of bone formation or for the prevention or alleviation of a cartilage disorder or a joint disease.
- (c) A method for promoting bone formation, the method comprising administering, to a mammal, an effective amount of the peptide of the present invention or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- (d) A method for preventing or alleviating a cartilage disorder or a joint disease, the method comprising administering, to a mammal, an effective amount of the peptide of the present invention or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- (e) A non-therapeutic method for promoting bone formation, the method comprising orally administering, to a mammal, the peptide of the present invention or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- (f) A non-therapeutic method for preventing or alleviating a cartilage disorder or a joint disease, the method comprising orally administering, to a mammal, the peptide of the present invention or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof.
- (g) The peptide of the present invention or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof for use in the promotion of bone formation or for the prevention or alleviation of a cartilage disorder or a joint disease.
- (h) Use of the peptide of the present invention or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof for the promotion of bone formation or for the prevention or alleviation of a cartilage disorder or a joint disease.
- (i) Use of the peptide of the present invention or a derivative thereof or a salt thereof or lipovitellin-1 or a derivative thereof or a salt thereof for the production of a medicament for promoting bone formation or for preventing or alleviating a cartilage disorder or a joint disease.
- The present invention will be described in more detail below with reference to Examples, but the present invention is not limited thereto.
- (1) Preparation of Egg-Yolk Protein Hydrolysate
- To 100 parts by mass of defatted egg yolk powder (Kewpie Corporation), 500 parts by mass of water was added, and the mixture was stirred until uniform. To the mixture, 5 parts by mass of “Alcalase” (trade name) (protease from Bacillus licheniformis (Novozymes Japan Ltd.)) was added, and the mixture was allowed to react at
pH 7 at 55 to 60° C. for 3 hours. At the end of the reaction, the enzyme was inactivated by heating at 90° C. for 10 minutes. Filtration was performed and the filtrate was collected. The filtrate was spray-dried to give an egg-yolk protein hydrolysate. - Instead of the defatted egg yolk powder as used above, a defatted egg yolk powder prepared from a commercially available egg yolk powder (e.g., a product produced by Kewpie Corporation) may be used. Specifically, 5 to 10 parts by mass of ethanol (or n-hexane) is added to 1 part by mass of a commercially available egg yolk powder, then the mixture is stirred with a blender for about 30 minutes and filtered, and the solid is collected. This procedure is repeated about 3 times for removal of the fat from the egg yolk. The defatted egg yolk is then air-dried to give a defatted dry powder.
- (2) Measurement Method of Osteoblast Growth-Promoting Activity
- A mouse osteoblast-like cell line MC3T3-E1 Subclone-4 (ATCC No. CRL-2593) was cultured in α-MEM medium supplemented with 10% FBS at 5% CO2 and 95% air at 37° C. until confluent. The cells were collected by trypsinization. The collected cells were suspended at 1×104 cells/mL in fresh α-MEM medium. One mL of the cell suspension was seeded in each well of a 24-well plate, and precultured at 5% CO2 and 95% air at 37° C. On the next day, the medium was replaced with medium prepared by well mixing 50 μL of a sample or PBS (−) with 950 μL of fresh α-MEM medium supplemented with CaCl2 to a Ca concentration of 500 μg/mL. The cells were further cultured for 72 hours. The growth activity of osteoblasts was measured by the cell counting method. The activity of the sample for promoting the growth of osteoblasts was expressed in terms of the relative value, with the growth rate in the PBS (−) group taken as 100.
- (3) Fractionation with UF Membrane
- In 600 mL of water, 60 g of the egg-yolk protein hydrolysate was dissolved. The solution was fractionated with a UF membrane (cut off molecular weight: 1 kDa, Nihon Millipore, Ltd.). Osteoblast growth-promoting activity was determined for a fraction with a molecular weight of 1 kDa or less and a fraction with a molecular weight of 1 kDa or more. As a positive control, the unfractionated egg-yolk protein hydrolysate (1 mg/mL) was used. The fraction with a molecular weight of 1 kDa or less and the fraction with a molecular weight of 1 kDa or more were used in amounts equal to the corresponding amounts in the unfractionated egg-yolk protein hydrolysate (i.e., the corresponding amounts in 0.2 mg of the egg-yolk protein hydrolysate).
- The results are shown in
FIG. 1 . As is apparent fromFIG. 1 , the fraction with a molecular weight of 1 kDa or more showed osteoblast growth-promoting activity. - (4) Fractionation with Anion-Exchange Column
- The fraction with a molecular weight of 1 kDa or more, which showed osteoblast growth-promoting activity in the above (3), was further fractionated on an anion-exchange column (resin: Dowex, column size: 10 mm in diameter×63 mm) to give a flow-through fraction and fractions eluted with aqueous solutions with NaCl concentrations of 750 mM and 1 M. Osteoblast growth-promoting activity was determined for the fractions. As a positive control, the unfractionated egg-yolk protein hydrolysate (1 mg/mL) was used. The fractions were used in amounts equal to the corresponding amounts in the unfractionated egg-yolk protein hydrolysate (i.e., the corresponding amounts in 10 mg of the egg-yolk protein hydrolysate).
- The results are shown in
FIG. 2 . As is apparent fromFIG. 2 , the 750 mM NaCl eluate fraction showed the highest osteoblast growth-promoting activity. - (5) Fractionation by HPLC (First Round)
- The 750 mM NaCl eluate fraction, which showed the highest osteoblast growth-promoting activity in the above (4), was further fractionated on a C18 reverse-phase column (column size: 50 mm in diameter×250 mm). The fractions were collected at 1 minute intervals from elution time zero to 45 minute. The HPLC conditions were as follows.
-
- Column: C18 reverse-phase column,
- size: 50 mm in diameter×250 mm (HiPep Laboratories)
- Mobile phase: (A) 10% acetonitrile/0.1% TFA
- (B) 60% acetonitrile/0.1% TFA
-
B 5%→95% (40 min) gradient
- Detection: UV 215 nm
- Amount of samples: 601 mg
- Column: C18 reverse-phase column,
- In total, 45 fractions were collected, and every five fractions were combined to give G1 to G9 fractions (see
FIG. 3 ). Osteoblast growth-promoting activity was determined for G1 to G9 fractions. The fractions were used in amounts equal to the corresponding amounts in the unfractionated egg-yolk protein hydrolysate (i.e., the corresponding amounts in 66 mg of the egg-yolk protein hydrolysate). As a positive control, the unfractionated egg-yolk protein hydrolysate (1 mg/mL) was used. - The results are shown in
FIG. 4 . As is apparent fromFIG. 4 , G3 showed the highest osteoblast growth-promoting activity. - Osteoblast growth-promoting activity was further determined for the five fractions (
fractions 11 to 15) of G3 and the five fractions (fractions 16 to 20) of G4. The fractions were used in amounts equal to the corresponding amounts in the unfractionated egg-yolk protein hydrolysate (i.e., the corresponding amounts in 66 mg of the egg-yolk protein hydrolysate). As a positive control, the unfractionated egg-yolk protein hydrolysate (1 mg/mL) was used. - The results are shown in
FIG. 5 . As is apparent fromFIG. 5 , allfractions 11 to 20 showed higher osteoblast growth-promoting activity than the control. - (6) Fractionation by HPLC (Second Round)
- HPLC was performed on
fractions 11 to 20 under the following conditions. -
- Column: ODS-A (trade name) (10×4.6 mm I.D.) (YMC Co., Ltd.)
- Mobile phase: 4% acetonitrile/0.1% TFA (isocratic)
- Temperature: 40° C.
- Detection: UV 215 nm
- Amount of samples: 50 μg
- Of
fractions 11 to 20, two distinct peaks were detected in fraction 12 (seeFIG. 6 ), and accordinglyfraction 12 was further investigated. Briefly,fraction 12 was subjected to HPLC under the above conditions, and fractions withpeak 1 andpeak 2 were separated (seeFIG. 6 ). Osteoblast growth-promoting activity was determined for the fraction with peak 1 (peak 1), the fraction with peak 2 (peak 2), and a fraction other thanpeak 1 andpeak 2 fractions (Others). The fractions were used in amounts equal to the corresponding amounts in the unfractionated egg-yolk protein hydrolysate (i.e., the corresponding amounts in 133 mg of the egg-yolk protein hydrolysate). As a positive control, the unfractionated egg-yolk protein hydrolysate (1 mg/mL) was used. - The results are shown in
FIG. 7 . As is apparent fromFIG. 7 , the fraction withpeak 2 showed the highest osteoblast growth-promoting activity. - (7) Identification of Peptides
- The amino acid sequences of the peptides contained in the fraction with
peak 2 were analyzed using MALDI-TOF-MS (mass spectrometer). The analysis results revealed that at least six types of peptides were contained in the fraction withpeak 2 as shown inFIG. 8 . These peptides are fragments of lipovitellin-1 contained in egg yolk, and each correspond to the following positions in the amino acid sequence of lipovitellin-1 (SEQ ID NO: 8): No. 1, positions 1045-1052; No. 2, positions 1045-1051; No. 3, positions 1047-1051; No. 4, positions 1053-1059; No. 5, positions 1052-1059; and No. 6, positions 1045-1059. - The six types of peptides shown in Example 1 to have osteoblast growth-promoting activity were chemically synthesized and their osteoblast growth-promoting activities were determined. The peptide synthesis was performed with a SyroII automatic peptide synthesizer (Biotage Japan Ltd.).
- Osteoblast growth-promoting activity was determined for the synthetic peptides in the same manner as in Example 1. The synthetic peptides were added at 2.5, 5 or 10 μg/mL per well. As a control, PBS (−) was added. The osteoblast growth-promoting activity was expressed in terms of the relative value, with the growth rate in the PBS (−) group taken as 100.
-
FIG. 9 shows the results of No. 1,FIG. 10 shows the results of No. 2 and No. 3,FIG. 11 shows the results of No. 4 and No. 5, andFIG. 12 shows the results of No. 6. As is apparent fromFIGS. 9 to 12 , all the synthetic peptides promoted the growth of osteoblasts in a concentration-dependent manner. - One of the synthetic peptides (No. 1) or physiological saline (control) was administered to Sprague-Dawley male rats at three weeks old by oral gavage using a gastric tube once a day for four days. The dose of the synthetic peptide was 1, 10 or 100 mg/kg·day. As a positive control, human growth hormone (hGH) (Norditropin, Standard Commodity Classification No. of Japan: 872412) was subcutaneously administered at 20 μg/k·day once a day for four days. After the administration on
day 4, calcein was subcutaneously administered, and the rats were kept for one day. The rats were euthanized by bloodletting under anesthesia, and the tibiae were harvested. The tissue specimens of the tibial growth plates were prepared, and calcein deposition areas (fluorescent regions) on the tibial growth plates were measured under a fluorescent microscope to determine the longitudinal bone growth. - The results are shown in
FIG. 13 . As is apparent fromFIG. 13 , the increase in the height of the tibial growth plates was enhanced in a manner consistent with the increase in the dose of the synthetic peptide. The effect of enhancing the increase in the height by the synthetic peptide at the highest dose was comparable to the effect of the subcutaneous administration of the human growth hormone. The results revealed that oral administration of the peptides of the present invention promotes bone formation. - This study was performed using mouse-derived chondrogenic cell line ATDC5 (RIKEN BANK, RBC0565). ATDC5 cells in the logarithmic growth phase were suspended at 3×104 cells/mL in Eagle MEM medium supplemented with 5% FCS (fetal calf serum), and 100 μL of the cell suspension was seeded in each well of a 96-well plate and precultured at 5% CO2 and 95% air at 37° C. On the next day, the medium in each well was removed, and medium containing the synthetic peptide (No. 1 or No. 6) at 10 nmol/mL was added. The cells were cultured for 72 hours. As a control, medium without a synthetic peptide was added. The reaction solution (10 μg/well) of Cell Counting Kit-8 (Dojindo Laboratories) was added to each well. The plate was incubated for 3 hours, and the absorbance at 450 nm was measured with a microplate reader. The activity of the synthetic peptides for promoting the growth of chondrocytes was expressed in terms of the relative value, with the absorbance (growth rate) in the control group taken as 100%.
- The results are shown in
FIG. 14 . As is apparent fromFIG. 14 , synthetic peptide No. 6 and synthetic peptide No. 1 (a fragment of No. 6) showed chondrocyte growth-promoting effect. - This study was performed using the mouse-derived cell line ATDC5 as used in Example 4. ATDC5 cells in the logarithmic growth phase were seeded at 2×104 cells/mL per well in a 24-well plate containing DMEM/F-12 (1:1) medium supplemented with 5% FCS (fetal calf serum), 10 μg/mL transferrin and 3×10−8 M sodium selenite. The cells were precultured at 5% CO2 and 95% air at 37° C. On the next day, the medium in each well was removed, and medium containing the synthetic peptide (No. 1 or No. 6) at 10 nmol/mL was added. The cells were cultured for 72 hours. As a control, medium without a synthetic peptide was added. After 48 hours of culture, the culture supernatants were collected, and their hyaluronic acid concentrations were measured using QnE Hyaluronic Acid ELISA Assay (Biotech Trading Partners). The concentrations of hyaluronic acid in the culture supernatants of the synthetic peptide addition group were calculated by subtracting the absorbance of the background from the absorbance of the supernatants, and fitting the resulting values to the reference curve prepared using the standard.
- The results are shown in
FIG. 15 . As is apparent fromFIG. 15 , synthetic peptide No. 6 and synthetic peptide No. 1 (a fragment of No. 6) showed hyaluronic acid production-promoting effect. - Sprague-Dawley male rats at three weeks old were initially fed with a low-calcium diet (containing 0.05% calcium carbonate) for one week, and then fed with a normal diet (containing 1.2% calcium carbonate). The synthetic peptide (No. 1) or physiological saline (control) was administered to the rats by oral gavage using a gastric tube once a day for seven days. The dose of the synthetic peptide was 1, 10 or 100 mg/kg·day. After the oral administration on
day 7, the rats were euthanized by bloodletting under anesthesia, and the femurs and tibiae were harvested. The bone volume and bone morphology of the tibiae and femurs were measured by dual energy x-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT). The results revealed that the length, weight, and bone density of the tibiae tended to be higher in the synthetic peptide administration group than in the control group, indicating that the synthetic peptide promoted the recovery of the bone density loss due to calcium deficiency. - Female rats (eight months old, ten rats in each group) underwent ovariectomy (OVX), and synthetic peptide No. 1 was administered to the rats by oral gavage using a gastric tube once a day from the first postoperative day for six months. The dose of the synthetic peptide was 1, 10 or 100 mg/kg·day. The results revealed that the OVX-synthetic peptide administration group showed an increase in the bone density of the distal femoral metaphysis in a manner consistent with the increase in the dose of the synthetic peptide, and the increase was significant as compared with the OVX-control group (non-synthetic peptide administration group). The medium-dose administration group (10 mg/kg·day) and the high-dose administration group (100 mg/kg·day) showed an equal or higher bone density as compared with the sham operation group without removal of the ovary. Regarding the measured bone morphology parameters, the cancellous bone volume in the proximal tibial metaphysis increased in the OVX-synthetic peptide administration group in a manner consistent with the increase in the dose, and the increase was significant as compared with the OVX-control group. The medium-dose administration group and the high-dose administration group showed an equal or higher volume of the cancellous bone as compared with the sham operation group without removal of the ovary. OVX-induced reduction in the trabecular numbers and the trabecular width and OVX-induced increase in the trabecular separation tended to be inhibited in the OVX-synthetic peptide administration group.
- Synthetic peptide No. 1 was administered to mature female rats (eight months old, ten rats in each group) by oral gavage using a gastric tube once a day for 20 weeks. The dose of the synthetic peptide was 1, 10 or 100 mg/kg·day. As a positive control, alendronate sodium hydrate (hereinafter called “alendronate”) (300 μg/kg) was subcutaneously administered once a day for 20 weeks. The results revealed that the bone density in the femurs and the cancellous bone volume in the proximal tibial metaphysis at the end of the administration were significantly increased in the synthetic peptide administration group and the alendronate administration group as compared with the control group. The levels of the increases in the synthetic peptide administration group were comparable to those in the alendronate administration group.
- Synthetic peptide No. 1 was administered to aged female rats (13 to 14 months old, ten rats in each group) by oral gavage using a gastric tube once a day for 20 weeks. The dose of the synthetic peptide was 1, 10 or 100 mg/kg·day. As a positive control, the alendronate (300 μg/kg) was subcutaneously administered once a day for 20 weeks. The results revealed that the bone density in the femurs and the cancellous bone volume in the proximal tibial metaphysis increased in a dose-dependent manner in the synthetic peptide administration group.
- A crude fraction of osteoclasts was prepared from the long bones and scapulae of rabbits. The crude fraction was cultured on dentine slices in the presence of the synthetic peptides (0.0001 to 1000 μmol/L) for 48 hours, resulting in a reduction in the total area of pits in a concentration-dependent manner. Isolated osteoclasts were also prepared by collagen treatment of the crude fraction of osteoclasts. The isolated osteoclasts were pretreated with the synthetic peptides (0.0001 to 1000 μmol/L) for 15 minutes and then cultured on dentine slices for 24 hours, resulting in a reduction in the total area of pits in a concentration-dependent manner.
- Mouse mesenchymal stem cells 10T1/2 (JCRB accession No. JCRB9080) or ST2 (Riken BRC ID: RCB0224) were seeded at 5000 cells/well in a 96-well plate containing DMEM medium supplemented with 10% fetal bovine serum. The synthetic peptides were added to the wells at 0.1 to 100 nmol/mL, and the cells were cultured for 72 hours. Cell Counting Kit-8 (Dojindo Laboratories) was added at 10 μL/100 μL medium, and the plate was incubated at 37° C. for 1 to 4 hours. The absorbance at 450 nm was measured with a microplate reader. The results revealed that the addition of the synthetic peptides significantly increased the growth of 10T1/2 and ST2 cells.
- Mouse mesenchymal stem cells 10T1/2 or ST2 were seeded at 5000 cells/well in a 96-well plate containing DMEM medium supplemented with 10% fetal bovine serum. The synthetic peptides were added to the wells at 0.1 to 100 nmol/mL, and the cells were cultured for four days. The medium was replaced with DMEM medium supplemented with β-glycerophosphoric acid I (10 mM) and ascorbic acid (50 μg/mL). At this medium replacement, medium with or without the synthetic peptides was used for the examination of the effect of their presence. The cells were further cultured in the medium for three days (in total, seven days of culture). The cells were fixed, and stained for alkaline phosphatase activity using Alkaline Phosphatase Substrate Kit I (VECTOR Red) (Vector Laboratories). The results indicated strong alkaline phosphatase activity in the cells cultured in the presence of the synthetic peptides. The cells cultured in the absence of the synthetic peptides did not show such activity. That is, it was revealed that the addition of the synthetic peptides efficiently induced differentiation of undifferentiated mesenchymal stem cells into osteoblast-like cells (osteogenic cells) over a relatively short period of time of four days.
- Mouse EC (embryonic carcinoma)-derived cloned cell line ATDC5 (Riken BRC ID: RCB0565) with a potential to differentiate into chondrocytes was cultured in DMEM/F-12 medium supplemented with 5% FBS. The ATDC cells were seeded at 2×104 cells/well in a 48-well plate. After 24 hours of culture, the culture supernatant was removed, then DMEM/F-12 medium supplemented with 10 ng/mL insulin was added, and the synthetic peptides were added at 0.1 to 100 nmol/mL. As a positive control, 1 and 5 ng/mL BMP-2 or BMP-4 (R&D) was used. The medium was changed every 3 to 4 days.
- In order to investigate whether the synthetic peptides have a synergistic effect with BMP-2 or BMP-4, co-addition of the synthetic peptides at 0.1 to 100 nmol/mL with BMP-2 or BMP-4 at 1 ng/mL was performed. The cells were cultured for 14 days with periodical medium replacement. The cells were fixed in 10% formalin neutral buffer, and stained with Alcian-blue solution for 4 hours. After washing off the dye, the plate was dried and photographed.
- The results revealed that the mouse chondrogenic cells ATDC5 formed Alcian-blue-positive nodules by addition of the synthetic peptides, and the number of the nodules increased in a concentration-dependent manner. This fact indicated that the synthetic peptides induced the differentiation of the ATDC5 cells into chondrocytes. The synergistic effect with BMP-2 or BMP-4 was also indicated.
- Mouse osteoblast-like cell line MC3T3-E1 Subclone-4 (ATCC No. CRL-2593) was cultured at 5% CO2 and 95% air at 37° C. for 72 hours in 10% FBS-containing α-MEM medium with the addition of the synthetic peptides at 2.5, 5, or 10 μg/mL. After the end of culture, the alkaline phosphatase (ALP) activity of the osteoblast-like cells was measured by the p-nitrophenyl phosphate substrate method. The levels of osteocalcin (OCN) in the culture supernatants were determined by ELISA using an osteocalcin measurement kit (Takara Bio). The results indicated that the ALP activity and the OCN level had a tendency to increase depending on the concentration of the synthetic peptides added. ALP and OCN are considered to be the factors reflecting bone formation function, and thus the results suggested that the synthetic peptides promote the bone formation function of osteoblast-like cells via such related factors.
- One of the synthetic peptides (No. 1) or water for injection (control) was administered to Crlj:W1 male rats at four weeks old by oral gavage using a gastric tube once a day for seven days (n=3 in each group). The dose of the synthetic peptide (No. 1) was 100 mg/kg·day. As a positive control, human growth hormone (hGH) (Norditropin, Standard Commodity Classification No. of Japan: 872412) was subcutaneously administered at 500 μg/kg·day once a day for seven days. As fluorescent labels for the site of bone formation, tetracycline (20 mg/kg) was subcutaneously administered on
day 4 after the administration of the peptide or control, and then calcein (10 mg/kg) was subcutaneously administered onday 6 after the administration of the peptide or control. After the administration of the test sample onday 7, the rats were kept under fasting conditions. Twenty-four hours later, the blood was collected. The rats were then euthanized by bloodletting under anesthesia, and the tibiae were harvested (seeFIG. 16 ). Non-decalcified specimens of the proximal tibiae were prepared and photographed under a fluorescent microscope (BX-53, OLYMPUS). The bone morphology was measured using a morphometry system (Histometry RT digitizer, System Supply Co., Ltd.) and an analysis software (CSS-840 cancellous bone morphometry version, System Supply Co., Ltd.). The longitudinal growth rate (Lo.G.R.) in the growth cartilage, which is the increase in the height per day, was determined by measuring the distance between the tetracycline label and the calcein label, and dividing the distance by the administration interval between the fluorescent labels (two days). - The results revealed that the hGH administration group and the No. 1 administration group showed significant promotion of bone growth as compared with the control group, and that the bone growth-promoting effect observed in the No. 1 administration group was significant as compared with the hGH administration group (
FIG. 17 ). The No. 1 administration group also showed a high frequency of incorporation of the fluorescent labels into the primary cancellous bone as compared with the control group and the hGH administration group, suggesting that the synthetic peptide induced fast formation of the cancellous bone in the growth phase (FIG. 18 , white region). - The measurement of the serum level of insulin-like growth factor (IGF-1) by ELISA (Mouse/Rat IGF-I Quantikine ELISA Kit (MG100), R&D Systems, Inc.) revealed that the IGF-1 levels in the hGH administration group and the No. 1 administration group were higher than that in the control group (
FIG. 19 ). The increase in the level of IGF-1, which is related to growth of the bones and muscles in a growth phase, may contribute to the bone growth-promoting effect. - It is apparent from the above results that oral administration of the peptides of the present invention promotes longitudinal bone growth and the formation of the cancellous bone, which is the internal structure of the bone.
- One of the synthetic peptides (No. 1) or water for injection (control) was administered to Crlj:W1 male rats at four weeks old by oral gavage using a gastric tube once a day for 21 days (n=3 in each group). The dose of the synthetic peptide was 100 mg/kg·day. As a positive control, human growth hormone (hGH) (Norditropin, Standard Commodity Classification No. of Japan: 872412) was subcutaneously administered at 500 μg/kg·day once a day for 21 days. As fluorescent labels for the site of bone formation, tetracycline (20 mg/kg) was subcutaneously administered on
day 18 after the administration of the peptide or control, and then calcein (10 mg/kg) was subcutaneously administered onday 20 after the administration of the peptide or control. After the administration of the test sample onday 21, the rats were kept under fasting conditions. - Twenty-four hours later, the rats were euthanized by bloodletting under anesthesia, and the tibiae were harvested (see
FIG. 20 ). Non-decalcified specimens of the proximal tibiae were prepared and photographed under a fluorescent microscope (BX-53, OLYMPUS). The bone morphology was measured using a morphometry system (Histometry RT digitizer, System Supply Co., Ltd.) and an analysis software (CSS-840 cancellous bone morphometry version, System Supply Co., Ltd.). The longitudinal growth rate (Lo.G.R.) in the epiphyseal cartilage, which is the increase in the height per day, was determined by measuring the distance between the tetracycline label and the calcein label, and dividing the distance by the administration interval between the fluorescent labels (two days). - The results revealed that the hGH administration group and the No. 1 administration group showed significant promotion of bone growth as compared with the control group, and that the bone growth-promoting effect observed in the No. 1 administration group was significant as compared with the hGH administration group (
FIG. 21 ). It was thus indicated that long-term oral administration of the peptides of the present invention also promotes longitudinal bone growth. - The analysis of the secondary cancellous bone volume (bone volume/tissue volume (BV/TV)) by the above analysis system revealed that the No. 1 administration group had a higher secondary cancellous bone volume than the control group and the hGH administration group (
FIG. 22 ). The No. 1 administration group also showed a high percentage of the bone surface occupied by osteoblasts relative to the total bone surface (osteoblast surface/bone surface (Ob.S/BS)) (FIG. 23 ) and a low percentage of the bone surface occupied by osteoclasts relative to the total bone surface (osteoclast surface/Bone surface (Oc.S/BS)) (FIG. 24 ). - It is apparent from the above results that oral administration of the peptides of the present invention potentially induces skeletal metabolism in which bone formation is dominant via an increase of osteoblasts and inhibition of differentiation into osteoclasts.
- One of the synthetic peptides (No. 1) or water for injection (control) was administered to Crlj:W1 male rats at four weeks old by oral gavage using a gastric tube once a day for seven days (n=10 in each group). The dose of the synthetic peptide was 1, 10 or 100 mg/kg·day. As a positive control, human growth hormone (hGH) (Norditropin, Standard Commodity Classification No. of Japan: 872412) was subcutaneously administered at 500 μg/kg·day once a day for seven days. As fluorescent labels for the site of bone formation, tetracycline (20 mg/kg) was subcutaneously administered on
day 4 after the administration of the peptide or control, and then calcein (10 mg/kg) was subcutaneously administered onday 6 after the administration of the peptide or control. After the administration of the test sample onday 7, the rats were kept under fasting conditions. Twenty-four hours later, the rats were euthanized by bloodletting under anesthesia, and the tibiae were harvested. Non-decalcified specimens of the proximal tibiae were prepared and photographed under a fluorescent microscope (BX-53, OLYMPUS). The bone morphology was measured using a morphometry system (Histometry RT digitizer, System Supply Co., Ltd.) and an analysis software (CSS-840 cancellous bone morphometry version, System Supply Co., Ltd.). The mineral apposition rate (MAR), per day, in the secondary cancellous bone was determined by measuring the distance between the tetracycline label and the calcein label in the secondary cancellous bone, and dividing the distance by the administration interval between the fluorescent labels (two days). The results revealed a significant increase in the mineral apposition rate in the hGH administration group and the No. 1 administration group as compared with the control group. The No. 1 administration group also showed a significant increase in the mineral apposition rate at a dose of 10 mg/kg·day or more as compared with the hGH administration group (FIG. 26 ). The No. 1 administration group also showed a high percentage of the bone surface occupied by osteoblasts relative to the total bone surface (osteoblast surface/bone surface (Ob.S/BS)) (FIG. 27 ) and a high number of osteoblasts relative to the bone tissue volume (number of osteoblasts/tissue volume (N.Ob/TV)) (FIG. 28 ). The increase in the mineral apposition rate in the secondary cancellous bone in the No. 1 administration group would have resulted from the increase in the number of osteoblasts. The bone formation rate calculated as the annual fractional volume of bone formed relative to the bone surface (bone formation rate/bone surface (BFR/BS)) resulted in high rates in the No. 1 administration group (FIG. 29 ). The No. 1 administration group also showed a significant increase in the bone formation rate at a dose of 10 mg/kg·day or more as compared with the control group. - It is apparent from the above results that oral administration of the peptides of the present invention promotes mineral apposition of the secondary cancellous bone and increases the bone formation rate.
- The present invention is not limited to each of the embodiments and Examples described above, and various modifications are possible within the scope of the claims. Embodiments obtainable by appropriately combining the technical means disclosed in different embodiments of the present invention are also included in the technical scope of the present invention. The contents of the scientific literature and the patent literature cited herein are hereby incorporated by reference in their entirety.
Claims (17)
1-32. (canceled)
33. A method for preventing, treating or alleviating a cartilage disorder or a joint disease, the method comprising administering, to a mammal in need thereof, an effective amount of the peptide having 100 amino acid residues or less comprising an amino acid sequence selected from
(b) an amino acid sequence derived from the amino acid sequence (a) by conservative substitution or deletion of 1 to 3 amino acids, and
(c) an amino acid sequence consisting of at least four contiguous amino acids of the amino acid sequence (a) or (b), or
a derivative thereof or a salt thereof.
34. The method according to claim 33 , wherein the peptide or a derivative thereof or a salt thereof can have at least one phosphorylated serine.
35. The method according to claim 33 , wherein the peptide or a derivative thereof or a salt thereof is a fragment of lipovitellin-1.
36. The method according to claim 33 , wherein the peptide or a derivative thereof or a salt thereof has one or more activity which is selected from the group consisting of promotion of chondrocyte growth, promotion of hyaluronic acid production, induction of chondrogenic cell differentiation, promotion of mesenchymal stem cell growth, induction of mesenchymal stem cell differentiation and increase of the serum level of insulin-like growth factor (IGF-1) in a mammal and promotion of osteoblast growth, inhibition of bone resorption.
37. The method according to claim 33 , wherein the peptide is administered orally.
38. The method according to claim 33 , wherein the peptide is included in a medicament, a food or drink, a supplement, a food additive or a cosmetic product.
39. The method according to claim 33 , wherein the peptide or a derivative thereof or a salt thereof, which consists of an amino acid sequence selected from
40. The method according to claim 39 , wherein the peptide or a salt thereof has one or more activity which is selected from the group consisting of promotion of chondrocyte growth, promotion of hyaluronic acid production, induction of chondrogenic cell differentiation, promotion of mesenchymal stem cell growth, induction of mesenchymal stem cell differentiation and increase of the serum level of insulin-like growth factor (IGF-1) in a mammal, promotion of osteoblast growth and inhibition of bone resorption.
41. A method for promoting bone formation, the method comprising administering, to a mammal in need thereof, an effective amount of the peptide having 100 amino acid residues or less comprising an amino acid sequence selected from
(a) Val-Asn-Pro-Glu-Ser-Glu-Glu-Glu-Asp-Glu-Ser-Ser-Pro-Tyr-Glu (SEQ ID NO:1),
(b) an amino acid sequence derived from the amino acid sequence (a) by conservative substitution or deletion of 1 to 3 amino acids, and
(c) an amino acid sequence consisting of at least four contiguous amino acids of the amino acid sequence (a) or (b), or
a derivative thereof or a salt thereof,
wherein the peptide can have at least one phosphorylated serine.
42. The method according to claim 41 , wherein the peptide or a derivative thereof or a salt thereof has one or more activity which is selected from the group consisting of promotion of chondrocyte growth, promotion of hyaluronic acid production, induction of chondrogenic cell differentiation, promotion of mesenchymal stem cell growth, induction of mesenchymal stem cell differentiation and increase of the serum level of insulin-like growth factor (IGF-1) in a mammal, promotion of osteoblast growth, and inhibition of bone resorption.
43. The method according to claim 41 , wherein the peptide is administered orally.
44. The method according to claim 41 , wherein the peptide is included in a medicament, a food or drink, a supplement, a food additive or a cosmetic product.
45. The method according to claim 41 , wherein said peptide consists of an amino acid sequence selected from the group consisting of
wherein the peptide does not have phosphorylated serine.
46. The method according to claim 45 , wherein the peptide or a salt thereof has one or more activity which is selected from the group consisting of promotion of chondrocyte growth, promotion of hyaluronic acid production, induction of chondrogenic cell differentiation, promotion of mesenchymal stem cell growth, induction of mesenchymal stem cell differentiation and increase of the serum level of insulin-like growth factor (IGF-1) in a mammal, promotion of osteoblast growth, inhibition of bone resorption.
47. A peptide or a derivative thereof or a salt thereof, which consists of an amino acid sequence selected from
wherein the peptide can have at least one phosphorylated serine.
48. The peptide or a derivative thereof or a salt thereof according to claim 47 , wherein the peptide or a derivative thereof or a salt thereof has one or more activity which is selected from the group consisting of promotion of chondrocyte growth, promotion of hyaluronic acid production, induction of chondrogenic cell differentiation, promotion of mesenchymal stem cell growth, induction of mesenchymal stem cell differentiation and increase of the serum level of insulin-like growth factor (IGF-1) in a mammal, promotion of bone formation, promotion of osteoblast growth, and inhibition of bone resorption.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/703,177 US20200157165A1 (en) | 2014-02-25 | 2019-12-04 | Peptides having osteoblast growth-promoting activity and use thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014034240 | 2014-02-25 | ||
JP2014-034240 | 2014-02-25 | ||
PCT/JP2015/055340 WO2015129726A1 (en) | 2014-02-25 | 2015-02-25 | Peptide having osteoblast proliferation-promoting activity and use thereof |
US201615121471A | 2016-08-25 | 2016-08-25 | |
US16/703,177 US20200157165A1 (en) | 2014-02-25 | 2019-12-04 | Peptides having osteoblast growth-promoting activity and use thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/121,471 Division US10538564B2 (en) | 2014-02-25 | 2015-02-25 | Peptides having osteoblast growth-promoting activity and use thereof |
PCT/JP2015/055340 Division WO2015129726A1 (en) | 2014-02-25 | 2015-02-25 | Peptide having osteoblast proliferation-promoting activity and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200157165A1 true US20200157165A1 (en) | 2020-05-21 |
Family
ID=54009042
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/121,471 Active US10538564B2 (en) | 2014-02-25 | 2015-02-25 | Peptides having osteoblast growth-promoting activity and use thereof |
US16/703,177 Abandoned US20200157165A1 (en) | 2014-02-25 | 2019-12-04 | Peptides having osteoblast growth-promoting activity and use thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/121,471 Active US10538564B2 (en) | 2014-02-25 | 2015-02-25 | Peptides having osteoblast growth-promoting activity and use thereof |
Country Status (5)
Country | Link |
---|---|
US (2) | US10538564B2 (en) |
EP (1) | EP3112459A4 (en) |
JP (1) | JP6411455B2 (en) |
CN (1) | CN106029685A (en) |
WO (1) | WO2015129726A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109219443A (en) * | 2016-06-27 | 2019-01-15 | 富尔玛株式会社 | The prevention of osteogenesis imperfecta etc. and/or healing potion |
CN110950927B (en) * | 2019-12-04 | 2022-05-20 | 广州领晟医疗科技有限公司 | Peptide GGS11 for promoting cartilage regeneration and application thereof |
CN111533801A (en) * | 2020-05-18 | 2020-08-14 | 上海大学 | Novel glycosylated teriparatide derivative and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0453471A (en) * | 1990-06-22 | 1992-02-21 | Snow Brand Milk Prod Co Ltd | Bone-enriched food, feed and medicine |
US5366871A (en) | 1991-11-13 | 1994-11-22 | The University Of Utah | Ubiquitin-peptide extensions as enzyme substrates |
JP4273230B2 (en) | 2004-10-21 | 2009-06-03 | 国立大学法人広島大学 | Gene replacement vectors targeting birds and uses thereof |
JP5297676B2 (en) | 2008-04-02 | 2013-09-25 | クラレノリタケデンタル株式会社 | Composite biomaterial |
CN101700122A (en) * | 2009-08-18 | 2010-05-05 | 吉林大学 | Formula and preparation method of phosvitin phosphoeptide milk flavor calcium tablet |
JP2011211979A (en) | 2010-03-31 | 2011-10-27 | Pharma Foods International Co Ltd | Peptide having osteoblast proliferation promotion activity and use thereof |
CA2838262C (en) * | 2011-06-10 | 2019-05-21 | Jianping Wu | Methods of phosvitin extraction and phosphopeptide preparation from egg yolk |
JP6301831B2 (en) | 2012-07-06 | 2018-03-28 | 株式会社ファーマフーズ | Chondrocyte proliferation promoter |
-
2015
- 2015-02-25 EP EP15755196.1A patent/EP3112459A4/en active Pending
- 2015-02-25 JP JP2016505249A patent/JP6411455B2/en active Active
- 2015-02-25 CN CN201580010279.4A patent/CN106029685A/en active Pending
- 2015-02-25 US US15/121,471 patent/US10538564B2/en active Active
- 2015-02-25 WO PCT/JP2015/055340 patent/WO2015129726A1/en active Application Filing
-
2019
- 2019-12-04 US US16/703,177 patent/US20200157165A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP6411455B2 (en) | 2018-10-24 |
EP3112459A4 (en) | 2017-10-18 |
JPWO2015129726A1 (en) | 2017-03-30 |
US20160362466A1 (en) | 2016-12-15 |
US10538564B2 (en) | 2020-01-21 |
CN106029685A (en) | 2016-10-12 |
WO2015129726A1 (en) | 2015-09-03 |
EP3112459A1 (en) | 2017-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200157165A1 (en) | Peptides having osteoblast growth-promoting activity and use thereof | |
RU2388485C2 (en) | Glucagon-like peptide-1 secretagogue, foodstuffs and beverages stimulating clucagon-like peptide 1 secretion, postprandial hyperglycemia inhibitor and foodstuffs and beverages inhibiting postprandial hyperglycemia | |
US10463592B2 (en) | Peptide with anti-aging effect and use thereof | |
US10676507B2 (en) | Peptide and composition containing the same for anti-inflammation, anti-fibrosis, wound healing, and anticancer treatment | |
US20210128640A1 (en) | Hyaluronic acid production promoting agent | |
KR20070121639A (en) | Egg-derived bone-strengthening composition | |
JP2005213260A (en) | Protease inhibitor | |
KR102163445B1 (en) | Composition comprising chp (cyclo-his pro) for preventing, improving or treating of bone loss related disease | |
JP5980519B2 (en) | AMPK activator | |
US11241475B2 (en) | Preventive and/or therapeutic agent for osteogenesis imperfecta and other diseases | |
US20230272009A1 (en) | Peptide, Peptide Salt, Pharmaceutical Composition and Biological Tissue Calcification Inhibitor | |
KR102115353B1 (en) | Composition comprising chp (cyclo-his pro) and pth for preventing, improving or treating of bone loss related disease | |
JP2023048160A (en) | Composition for inhibiting osteoclast differentiation, increasing muscle mass, improving motor function, and/or enhancing muscle strength | |
JP2019085380A (en) | Hyaluronic acid production promoter | |
KR20050003989A (en) | Egg derivatives having bone-strengthening effects | |
JP2004346020A (en) | Protease inhibitor | |
JP5950395B2 (en) | Lipid metabolism improving agent containing ovalbumin degradation product |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |